Q2 0001109354 false 12-31 http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense http://fasb.org/us-gaap/2023#ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest http://fasb.org/us-gaap/2023#ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest http://fasb.org/us-gaap/2023#ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest http://fasb.org/us-gaap/2023#ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest 2023-05-31 0001109354 us-gaap:ParentMember 2022-04-01 2022-06-30 0001109354 brkr:ContingentConsiderationMember 2023-06-30 0001109354 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-06-30 0001109354 us-gaap:NoncontrollingInterestMember 2022-06-30 0001109354 us-gaap:RetainedEarningsMember 2023-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:ForeignExchangeForwardMember 2022-12-31 0001109354 us-gaap:IntersegmentEliminationMember 2023-04-01 2023-06-30 0001109354 country:CN 2022-04-01 2022-06-30 0001109354 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001109354 us-gaap:CustomerRelationshipsMember brkr:ZontalIncMember 2023-05-04 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2022-04-01 2022-06-30 0001109354 brkr:May2021RepurchaseProgramMember 2021-05-31 0001109354 brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:EnergyAndSuperconTechnologiesMember 2022-12-31 0001109354 brkr:MestrelabPreomicsBiognosysAcquisitionsAndMajorityOwnedAcquisitionMember 2023-04-01 2023-06-30 0001109354 us-gaap:ProductMember 2022-01-01 2022-06-30 0001109354 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-06-30 0001109354 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerNanoGroupMember 2023-01-01 2023-06-30 0001109354 brkr:RestOfAsiaPacificMember 2023-04-01 2023-06-30 0001109354 brkr:CapitalLeaseObligationsAndOtherLoanMember 2022-12-31 0001109354 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerCalidGroupMember 2022-04-01 2022-06-30 0001109354 us-gaap:CashFlowHedgingMember 2023-04-01 2023-06-30 0001109354 us-gaap:InterestIncomeMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:ForeignExchangeForwardMember 2023-04-01 2023-06-30 0001109354 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001109354 brkr:May2021RepurchaseProgramMember 2023-01-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember us-gaap:NetInvestmentHedgingMember us-gaap:LongTermDebtMember 2023-01-01 2023-06-30 0001109354 us-gaap:TransferredOverTimeMember 2023-04-01 2023-06-30 0001109354 brkr:RedeemableNoncontrollingInterestMember 2022-04-01 2022-06-30 0001109354 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001109354 brkr:CorporateReconcilingItemsAndEliminationsMember 2023-06-30 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:InterestIncomeMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2023-01-01 2023-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2023-01-01 2023-06-30 0001109354 us-gaap:RetainedEarningsMember 2022-12-31 0001109354 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:ForeignExchangeForwardMember 2023-01-01 2023-06-30 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001109354 us-gaap:TransferredOverTimeMember 2022-01-01 2022-06-30 0001109354 brkr:IncentiveCompensationPlan2016Member 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentAssetsMember 2022-12-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember us-gaap:OtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001109354 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001109354 us-gaap:ParentMember 2022-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:ScientificInstrumentsMember 2023-01-01 2023-06-30 0001109354 us-gaap:ParentMember 2023-03-31 0001109354 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001109354 us-gaap:ParentMember 2023-06-30 0001109354 us-gaap:CustomerRelationshipsMember 2022-12-31 0001109354 us-gaap:OperatingSegmentsMember brkr:BsiNanoMember 2023-04-01 2023-06-30 0001109354 us-gaap:RetainedEarningsMember 2022-06-30 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001109354 us-gaap:ParentMember 2022-12-31 0001109354 us-gaap:ParentMember 2022-03-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2023-04-01 2023-06-30 0001109354 brkr:CorporateReconcilingItemsAndEliminationsMember 2023-04-01 2023-06-30 0001109354 brkr:OtherCountryMember 2023-04-01 2023-06-30 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-06-30 0001109354 2023-06-30 0001109354 brkr:ZontalIncMember 2023-05-04 2023-05-04 0001109354 us-gaap:CommonStockMember 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember us-gaap:LongTermDebtMember 2022-01-01 2022-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:ScientificInstrumentsMember 2023-04-01 2023-06-30 0001109354 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-06-30 0001109354 us-gaap:CommonStockMember 2022-12-31 0001109354 country:US 2022-01-01 2022-06-30 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2022-12-31 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2023-04-01 2023-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2023-04-01 2023-06-30 0001109354 us-gaap:OtherExpenseMember 2023-04-01 2023-06-30 0001109354 brkr:RedeemableNoncontrollingInterestMember 2022-12-31 0001109354 brkr:RestOfAsiaPacificMember 2022-01-01 2022-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BsiCalidMember 2022-04-01 2022-06-30 0001109354 2023-01-01 2023-03-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:OtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001109354 brkr:TermLoanAgreementMember 2022-12-31 0001109354 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001109354 us-gaap:CommonStockMember 2023-06-30 0001109354 brkr:May2023RepurchaseProgramMember 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember us-gaap:InterestIncomeMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2022-01-01 2022-06-30 0001109354 brkr:TomeBiosciencesIncMember us-gaap:SubsequentEventMember 2023-07-26 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:ForeignExchangeForwardMember 2022-04-01 2022-06-30 0001109354 us-gaap:CostOfSalesMember 2022-01-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2022-01-01 2022-06-30 0001109354 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerCalidGroupMember 2023-04-01 2023-06-30 0001109354 us-gaap:DomesticLineOfCreditMember brkr:RevolvingCreditAgreement2019Member 2023-06-30 0001109354 2022-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:BsiNanoMember 2022-01-01 2022-06-30 0001109354 brkr:May2023RepurchaseProgramMember 2023-05-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember 2022-04-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:OtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001109354 us-gaap:ProductMember 2022-04-01 2022-06-30 0001109354 us-gaap:OrderOrProductionBacklogMember brkr:ZontalIncMember 2023-05-04 0001109354 brkr:MestrelabPreomicsBiognosysAcquisitionsAndMajorityOwnedAcquisitionMember 2022-01-01 2022-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:EnergyAndSuperconTechnologiesMember 2022-04-01 2022-06-30 0001109354 brkr:CorporateReconcilingItemsAndEliminationsMember 2022-04-01 2022-06-30 0001109354 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001109354 brkr:RedeemableNoncontrollingInterestMember 2023-04-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember us-gaap:LongTermDebtMember 2023-01-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember us-gaap:InterestIncomeMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2022-04-01 2022-06-30 0001109354 brkr:NotePurchaseAgreement2012Member 2022-12-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001109354 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001109354 brkr:RedeemableNoncontrollingInterestMember 2023-01-01 2023-03-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-06-30 0001109354 brkr:BiognosysAgMember 2023-01-01 2023-06-30 0001109354 country:CH 2023-01-01 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerNanoGroupMember 2022-01-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherAssetsMember 2023-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:ForeignExchangeForwardMember 2023-06-30 0001109354 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-06-30 0001109354 us-gaap:FacilityClosingMember 2022-12-31 0001109354 us-gaap:TreasuryStockCommonMember 2023-03-31 0001109354 us-gaap:RetainedEarningsMember 2023-03-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:OtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001109354 brkr:RestOfEuropeMember 2022-04-01 2022-06-30 0001109354 brkr:RestOfEuropeMember 2023-04-01 2023-06-30 0001109354 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:OtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001109354 brkr:BiognosysAgMember 2023-01-03 2023-01-03 0001109354 brkr:TermLoanAgreementMember 2023-06-30 0001109354 us-gaap:TransferredOverTimeMember 2023-01-01 2023-06-30 0001109354 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001109354 us-gaap:ParentMember 2021-12-31 0001109354 us-gaap:CashFlowHedgingMember 2023-01-01 2023-06-30 0001109354 country:US 2022-04-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0001109354 us-gaap:CommonStockMember 2023-03-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001109354 us-gaap:CashFlowHedgingMember 2022-04-01 2022-06-30 0001109354 brkr:AcquiferImagingGmbhAndDeltabyteGmbhMember 2023-01-04 2023-01-04 0001109354 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001109354 us-gaap:OperatingSegmentsMember 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerBioSpinGroupMember 2023-04-01 2023-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BsiCalidMember 2022-01-01 2022-06-30 0001109354 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentAssetsMember 2022-12-31 0001109354 us-gaap:TransferredOverTimeMember 2022-04-01 2022-06-30 0001109354 country:DE 2022-04-01 2022-06-30 0001109354 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001109354 brkr:OtherMajorityOwnedAcquisitionsMember 2023-06-30 2023-06-30 0001109354 brkr:RedeemableNoncontrollingInterestMember 2022-03-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2022-01-01 2022-06-30 0001109354 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001109354 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:OtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2023-01-01 2023-06-30 0001109354 us-gaap:TreasuryStockCommonMember 2022-12-31 0001109354 us-gaap:ProductAndServiceOtherMember 2023-04-01 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:ScientificInstrumentsMember 2022-01-01 2022-06-30 0001109354 2023-04-01 2023-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentAssetsMember 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:EnergyAndSuperconTechnologiesMember 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:EnergyAndSuperconTechnologiesMember 2023-01-01 2023-06-30 0001109354 brkr:ProvisionsForExcessInventoryMember 2022-12-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2022-04-01 2022-06-30 0001109354 us-gaap:TechnologyBasedIntangibleAssetsMember brkr:BiognosysAgMember 2023-01-03 0001109354 brkr:May2023RepurchaseProgramMember 2023-04-01 2023-06-30 0001109354 brkr:EmployeeStockPurchasePlanMember 2022-04-01 2022-06-30 0001109354 brkr:ZontalIncMember us-gaap:TradeNamesMember 2023-05-04 0001109354 2022-04-01 2022-06-30 0001109354 2021-12-31 0001109354 brkr:May2023RepurchaseProgramMember 2023-01-01 2023-06-30 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2023-04-01 2023-06-30 0001109354 country:DE 2023-04-01 2023-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:CommodityContractMember 2022-12-31 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:OtherCurrentAssetsMember 2022-12-31 0001109354 us-gaap:TechnologyBasedIntangibleAssetsMember brkr:ZontalIncMember 2023-05-04 0001109354 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2022-01-01 2022-06-30 0001109354 us-gaap:EmployeeSeveranceMember 2022-12-31 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:InterestIncomeMember 2023-04-01 2023-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:ForeignExchangeForwardMember 2022-01-01 2022-06-30 0001109354 us-gaap:TreasuryStockCommonMember 2022-03-31 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2022-01-01 2022-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:CommodityContractMember 2023-06-30 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:OtherCurrentAssetsMember 2023-06-30 0001109354 brkr:BiognosysAgMember 2023-01-01 2023-03-31 0001109354 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerBioSpinGroupMember 2022-01-01 2022-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2022-12-31 0001109354 brkr:InvestmentInBusinessesMember brkr:OtherInvestmentMember 2023-01-01 2023-06-30 0001109354 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-06-30 0001109354 us-gaap:NoncontrollingInterestMember 2022-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerNanoGroupMember 2023-04-01 2023-06-30 0001109354 country:US 2023-04-01 2023-06-30 0001109354 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001109354 us-gaap:FacilityClosingMember 2023-06-30 0001109354 brkr:EmployeeStockPurchasePlanMember 2023-01-01 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BsiCalidMember 2023-04-01 2023-06-30 0001109354 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0001109354 brkr:ContingentConsiderationMember 2023-01-01 2023-06-30 0001109354 brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2022-12-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001109354 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:EnergyAndSuperconTechnologiesMember 2023-04-01 2023-06-30 0001109354 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-06-30 0001109354 brkr:RestOfAsiaPacificMember 2023-01-01 2023-06-30 0001109354 country:CN 2022-01-01 2022-06-30 0001109354 us-gaap:CostOfSalesMember 2022-04-01 2022-06-30 0001109354 brkr:RedeemableNoncontrollingInterestMember 2021-12-31 0001109354 us-gaap:TradeNamesMember 2023-06-30 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-06-30 0001109354 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0001109354 brkr:RestOfEuropeMember 2022-01-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2023-04-01 2023-06-30 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0001109354 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001109354 brkr:OtherCountryMember 2022-01-01 2022-06-30 0001109354 brkr:RedeemableNoncontrollingInterestMember 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2023-01-01 2023-06-30 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:InterestIncomeMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2022-01-01 2022-06-30 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:InterestIncomeMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2022-04-01 2022-06-30 0001109354 brkr:May2021RepurchaseProgramMember 2023-06-30 0001109354 brkr:OtherLoanMember 2023-06-30 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:ForeignExchangeForwardMember 2023-04-01 2023-06-30 0001109354 us-gaap:ProductMember 2023-01-01 2023-06-30 0001109354 brkr:RedeemableNoncontrollingInterestMember 2022-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember 2022-12-31 0001109354 brkr:CorporateReconcilingItemsAndEliminationsMember 2023-01-01 2023-06-30 0001109354 brkr:MestrelabPreomicsBiognosysAcquisitionsAndMajorityOwnedAcquisitionMember 2023-01-01 2023-06-30 0001109354 brkr:May2021RepurchaseProgramMember 2023-04-01 2023-06-30 0001109354 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-06-30 0001109354 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001109354 us-gaap:ParentMember 2023-04-01 2023-06-30 0001109354 brkr:SwitzerlandFrancsNotesUnderThe2021NotesPurchaseAgreementMember 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:OtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001109354 us-gaap:CommonStockMember 2021-12-31 0001109354 us-gaap:OtherExpenseMember 2023-01-01 2023-06-30 0001109354 us-gaap:TreasuryStockCommonMember 2021-12-31 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2022-12-31 0001109354 us-gaap:HybridInstrumentMember 2022-12-31 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001109354 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember us-gaap:LongTermDebtMember 2023-04-01 2023-06-30 0001109354 brkr:MestrelabPreomicsBiognosysAcquisitionsAndMajorityOwnedAcquisitionMember 2022-04-01 2022-06-30 0001109354 brkr:UnvestedRestrictedStockUnitsRsuMember 2023-01-01 2023-06-30 0001109354 brkr:NotePurchaseAgreement2019Member 2022-12-31 0001109354 us-gaap:EmployeeSeveranceMember 2023-06-30 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember 2022-12-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001109354 us-gaap:TransferredAtPointInTimeMember 2023-04-01 2023-06-30 0001109354 brkr:May2021RepurchaseProgramMember 2022-01-01 2022-06-30 0001109354 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0001109354 us-gaap:OtherIntangibleAssetsMember 2023-06-30 0001109354 us-gaap:CostOfSalesMember 2023-01-01 2023-06-30 0001109354 brkr:ContingentConsiderationMember 2022-12-31 0001109354 brkr:RedeemableNoncontrollingInterestMember 2022-01-01 2022-03-31 0001109354 brkr:EmployeeStockPurchasePlanMember 2022-01-01 2022-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:InterestIncomeMember us-gaap:ForeignExchangeForwardMember 2022-01-01 2022-06-30 0001109354 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001109354 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongTermDebtMember 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BsiCalidMember 2023-01-01 2023-06-30 0001109354 brkr:CorporateReconcilingItemsAndEliminationsMember 2022-12-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember us-gaap:OtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001109354 us-gaap:OtherExpenseMember 2022-01-01 2022-06-30 0001109354 brkr:InvestmentInBusinessesMember 2023-01-01 2023-06-30 0001109354 brkr:UnvestedRestrictedStockUnitsRsuMember 2022-04-01 2022-06-30 0001109354 brkr:USToEuroCrossCurrencyAndInterestRateSwapAgreementsMember 2023-06-30 0001109354 us-gaap:NoncontrollingInterestMember 2022-12-31 0001109354 us-gaap:NoncontrollingInterestMember 2023-06-30 0001109354 us-gaap:PendingLitigationMember 2023-06-30 0001109354 us-gaap:CostOfSalesMember 2023-04-01 2023-06-30 0001109354 brkr:ZontalIncMember 2023-01-01 2023-06-30 0001109354 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001109354 us-gaap:ProductMember 2023-04-01 2023-06-30 0001109354 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember us-gaap:InterestIncomeMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2023-04-01 2023-06-30 0001109354 brkr:UnvestedRestrictedStockUnitsRsuMember 2023-04-01 2023-06-30 0001109354 us-gaap:TransferredAtPointInTimeMember 2022-04-01 2022-06-30 0001109354 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2023-01-01 2023-06-30 0001109354 us-gaap:NoncontrollingInterestMember 2021-12-31 0001109354 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001109354 brkr:BankGuaranteesAndWorkingCapitalLineMember 2023-06-30 0001109354 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001109354 us-gaap:CustomerRelationshipsMember brkr:BiognosysAgMember 2023-01-03 0001109354 2023-08-04 0001109354 brkr:CorporateReconcilingItemsAndEliminationsMember 2022-01-01 2022-06-30 0001109354 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001109354 brkr:USToSwissFrancCrossCurrencyAndInterestRateSwapAgreementsMember 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerCalidGroupMember 2023-01-01 2023-06-30 0001109354 us-gaap:TradeNamesMember 2022-12-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2022-04-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2023-01-01 2023-06-30 0001109354 us-gaap:HybridInstrumentMember 2023-01-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember us-gaap:NetInvestmentHedgingMember us-gaap:LongTermDebtMember 2023-04-01 2023-06-30 0001109354 brkr:OtherCountryMember 2023-01-01 2023-06-30 0001109354 country:CN 2023-04-01 2023-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2022-01-01 2022-06-30 0001109354 brkr:TofwerkAgMember 2023-06-30 0001109354 us-gaap:TreasuryStockCommonMember 2022-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember 2023-06-30 0001109354 us-gaap:OrderOrProductionBacklogMember brkr:BiognosysAgMember 2023-01-03 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember us-gaap:NetInvestmentHedgingMember us-gaap:LongTermDebtMember 2022-01-01 2022-06-30 0001109354 2022-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:ScientificInstrumentsMember 2022-04-01 2022-06-30 0001109354 brkr:NotePurchaseAgreement2019Member 2023-06-30 0001109354 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:OtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001109354 country:CN 2023-01-01 2023-06-30 0001109354 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001109354 brkr:EuroNotesUnderThe2021PurchaseAgreementMember 2022-12-31 0001109354 country:DE 2022-01-01 2022-06-30 0001109354 brkr:RedeemableNoncontrollingInterestMember 2023-03-31 0001109354 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001109354 brkr:OtherLoanMember 2022-12-31 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2023-06-30 0001109354 brkr:May2021RepurchaseProgramMember 2022-04-01 2022-06-30 0001109354 brkr:ElipticaLimitedMember 2023-06-30 0001109354 country:US 2023-01-01 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BsiNanoMember 2022-04-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentAssetsMember 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2022-01-01 2022-06-30 0001109354 brkr:EmployeeStockPurchasePlanMember 2023-04-01 2023-06-30 0001109354 brkr:RestOfAsiaPacificMember 2022-04-01 2022-06-30 0001109354 us-gaap:ProductAndServiceOtherMember 2022-04-01 2022-06-30 0001109354 brkr:BiognosysAgMember us-gaap:TradeNamesMember 2023-01-03 0001109354 2022-01-01 2022-03-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember 2023-04-01 2023-06-30 0001109354 2023-03-31 0001109354 us-gaap:ParentMember 2023-01-01 2023-03-31 0001109354 us-gaap:CommonStockMember 2022-03-31 0001109354 brkr:OtherCountryMember 2022-04-01 2022-06-30 0001109354 brkr:UnvestedRestrictedStockUnitsRsuMember 2022-01-01 2022-06-30 0001109354 brkr:ProvisionsForExcessInventoryMember 2023-01-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2023-04-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2022-04-01 2022-06-30 0001109354 country:DE 2023-01-01 2023-06-30 0001109354 us-gaap:PendingLitigationMember 2022-12-31 0001109354 us-gaap:TreasuryStockCommonMember 2023-06-30 0001109354 us-gaap:IntersegmentEliminationMember 2022-04-01 2022-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerBioSpinGroupMember 2023-01-01 2023-06-30 0001109354 2022-01-01 2022-12-31 0001109354 us-gaap:CashFlowHedgingMember 2022-01-01 2022-06-30 0001109354 brkr:ProvisionsForExcessInventoryMember 2023-06-30 0001109354 us-gaap:ParentMember 2022-01-01 2022-03-31 0001109354 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:EnergyAndSuperconTechnologiesMember 2022-01-01 2022-06-30 0001109354 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001109354 us-gaap:RetainedEarningsMember 2022-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:BsiNanoMember 2023-01-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongTermDebtMember 2022-12-31 0001109354 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember us-gaap:OtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001109354 us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-06-30 0001109354 brkr:RestOfEuropeMember 2023-01-01 2023-06-30 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001109354 brkr:EuroNotesUnderThe2021PurchaseAgreementMember 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2022-04-01 2022-06-30 0001109354 brkr:CapitalLeaseObligationsAndOtherLoanMember 2023-06-30 0001109354 us-gaap:NoncontrollingInterestMember 2023-03-31 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001109354 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001109354 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001109354 brkr:ZontalIncMember 2023-05-04 0001109354 brkr:BiognosysAgMember 2023-01-03 0001109354 us-gaap:InterestIncomeMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:ForeignExchangeForwardMember 2023-01-01 2023-06-30 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2022-04-01 2022-06-30 0001109354 brkr:SwitzerlandFrancsNotesUnderThe2021NotesPurchaseAgreementMember 2022-12-31 0001109354 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001109354 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001109354 us-gaap:CustomerRelationshipsMember 2023-06-30 0001109354 us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-06-30 0001109354 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember us-gaap:InterestIncomeMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2023-01-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember us-gaap:OtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001109354 us-gaap:RetainedEarningsMember 2021-12-31 0001109354 us-gaap:HybridInstrumentMember 2023-06-30 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:OtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001109354 2023-01-01 2023-06-30 0001109354 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001109354 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2022-04-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember us-gaap:LongTermDebtMember 2022-04-01 2022-06-30 0001109354 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0001109354 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001109354 2022-01-01 2022-06-30 0001109354 us-gaap:OtherExpenseMember 2022-04-01 2022-06-30 0001109354 2022-12-31 0001109354 us-gaap:FacilityClosingMember 2023-01-01 2023-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember brkr:CrossCurrencyAndInterestRateSwapAgreementsMember 2023-01-01 2023-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerNanoGroupMember 2022-04-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherAssetsMember 2022-12-31 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerBioSpinGroupMember 2022-04-01 2022-06-30 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember us-gaap:NetInvestmentHedgingMember us-gaap:LongTermDebtMember 2022-04-01 2022-06-30 0001109354 us-gaap:OperatingSegmentsMember brkr:BrukerCalidGroupMember 2022-01-01 2022-06-30 0001109354 brkr:NotePurchaseAgreement2012Member 2023-06-30 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-06-30 0001109354 brkr:IncentiveCompensationPlan2016Member 2023-01-01 2023-06-30 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:InterestIncomeMember us-gaap:ForeignExchangeForwardMember 2022-04-01 2022-06-30 0001109354 2022-08-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2023-04-01 2023-06-30 0001109354 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 iso4217:EUR xbrli:pure xbrli:shares iso4217:CHF brkr:Segment iso4217:USD iso4217:USD xbrli:shares

##### Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934

For the quarterly period ended June 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934

For the transition period from to

Commission File Number 000-30833

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

Delaware | 04-3110160
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)

40 Manning Road, Billerica, MA 01821

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (978) 663-3660

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbols(s) | Name of each exchange on which registered
Common Stock | BRKR | Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ | Accelerated filer | ☐
Non-accelerated filer | ☐ | Smaller reporting company | ☐
|  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class | Outstanding at August 4, 2023
Common Stock, $0.01 par value per share | 146,853,102 shares

##### Table of Contents

BRUKER CORPORATION

Quarterly Report on Form 10-Q

For the Quarter Ended June 30, 2023

|  | Page
Part I | FINANCIAL INFORMATION | 3
Item 1: | Unaudited Condensed Consolidated Financial Statements | 3
| Unaudited Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 | 3
| Unaudited Condensed Consolidated Statements of Income and Comprehensive Income for the three and six months ended June 30, 2023 and 2022 | 4
| Unaudited Condensed Consolidated Statements of Redeemable Noncontrolling Interests and Shareholders’ Equity for the three and six months ended June 30, 2023 and 2022 | 5
| Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022 | 7
| Notes to Unaudited Condensed Consolidated Financial Statements | 8
Item 2: | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 26
Item 3: | Quantitative and Qualitative Disclosures About Market Risk | 39
Item 4: | Controls and Procedures | 41
Part II | OTHER INFORMATION | 42
Item 1: | Legal Proceedings | 42
Item 1A: | Risk Factors | 42
Item 2: | Unregistered Sales of Equity Securities and Use of Proceeds | 42
Item 5: | Other Information | 42
Item 6: | Exhibits | 43
| Signatures | 44

2

##### Table of Contents

PART I FINANCIAL INFORMATION

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except share and per share data)

|  | June 30, 2023 |  |  | December 31, 2022 |
ASSETS |  |  |  |  |  |
Current assets: |  |  |  |  |  |
Cash and cash equivalents |  | $ | 574.8 |  |  | $ | 645.5 |
Accounts receivable, net |  |  | 450.8 |  |  |  | 472.7 |
Inventories |  |  | 914.6 |  |  |  | 800.1 |
Assets held for sale |  |  | — |  |  |  | 1.4 |
Other current assets |  |  | 243.1 |  |  |  | 193.5 |
Total current assets |  |  | 2,183.3 |  |  |  | 2,113.2 |
Property, plant and equipment, net |  |  | 522.7 |  |  |  | 487.0 |
Goodwill |  |  | 557.9 |  |  |  | 457.6 |
Intangible assets, net |  |  | 300.4 |  |  |  | 270.9 |
Other long-term assets |  |  | 292.7 |  |  |  | 283.1 |
Total assets |  | $ | 3,857.0 |  |  | $ | 3,611.8 |
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS’ EQUITY |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |
Current portion of long-term debt |  | $ | 120.9 |  |  | $ | 18.7 |
Accounts payable |  |  | 188.8 |  |  |  | 178.4 |
Deferred revenue and customer advances |  |  | 397.4 |  |  |  | 370.2 |
Other current liabilities |  |  | 343.8 |  |  |  | 347.0 |
Total current liabilities |  |  | 1,050.9 |  |  |  | 914.3 |
Long-term debt |  |  | 1,122.5 |  |  |  | 1,200.5 |
Other long-term liabilities |  |  | 421.0 |  |  |  | 365.2 |
Commitments and contingencies (Note 16) |  |  |  |  |  |
Redeemable noncontrolling interests |  |  | 11.9 |  |  |  | 6.1 |
Shareholders’ equity: |  |  |  |  |  |
Preferred stock, $0.01 par value 5,000,000 shares authorized, no ne issued or outstanding |  |  | — |  |  |  | — |
Common stock, $0.01 par value 260,000,000 shares authorized, 175,498,835 and 175,389,586 shares issued and 146,817,075 and 147,023,144 shares outstanding at June 30, 2023 and December 31, 2022, respectively |  |  | 1.7 |  |  |  | 1.7 |
Treasury stock, at cost, 28,681,760 and 28,366,442 shares at June 30, 2023 and December 31, 2022, respectively |  |  | (1,107.2 | ) |  |  | (1,085.0 | )
Accumulated other comprehensive income, net of tax |  |  | 24.4 |  |  |  | 14.8 |
Other shareholders’ equity |  |  | 2,312.3 |  |  |  | 2,182.3 |
Total shareholders’ equity attributable to Bruker Corporation |  |  | 1,231.2 |  |  |  | 1,113.8 |
Noncontrolling interests in consolidated subsidiaries |  |  | 19.5 |  |  |  | 11.9 |
Total shareholders’ equity |  |  | 1,250.7 |  |  |  | 1,125.7 |
Total liabilities, redeemable noncontrolling interests and shareholders’ equity |  | $ | 3,857.0 |  |  | $ | 3,611.8 |

The accompanying notes are an integral part of these financial statements.

3

##### Table of Contents

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(in millions, except per share data)

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Product revenue |  | $ | 559.6 |  |  | $ | 485.8 |  |  | $ | 1,126.7 |  |  | $ | 976.2 |
Service and other revenue |  |  | 122.3 |  |  |  | 102.6 |  |  |  | 240.5 |  |  |  | 207.2 |
Total revenue |  |  | 681.9 |  |  |  | 588.4 |  |  |  | 1,367.2 |  |  |  | 1,183.4 |
Cost of product revenue |  |  | 272.8 |  |  |  | 230.1 |  |  |  | 530.0 |  |  |  | 459.1 |
Cost of service and other revenue |  |  | 68.6 |  |  |  | 60.1 |  |  |  | 137.0 |  |  |  | 119.8 |
Total cost of revenue |  |  | 341.4 |  |  |  | 290.2 |  |  |  | 667.0 |  |  |  | 578.9 |
Gross profit |  |  | 340.5 |  |  |  | 298.2 |  |  |  | 700.2 |  |  |  | 604.5 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Selling, general and administrative |  |  | 177.9 |  |  |  | 152.2 |  |  |  | 340.6 |  |  |  | 297.9 |
Research and development |  |  | 71.0 |  |  |  | 59.6 |  |  |  | 140.0 |  |  |  | 116.2 |
Other charges, net |  |  | 5.4 |  |  |  | 12.5 |  |  |  | 10.7 |  |  |  | 20.0 |
Total operating expenses |  |  | 254.3 |  |  |  | 224.3 |  |  |  | 491.3 |  |  |  | 434.1 |
Operating income |  |  | 86.2 |  |  |  | 73.9 |  |  |  | 208.9 |  |  |  | 170.4 |
Interest and other income (expense), net |  |  | (8.7 | ) |  |  | (4.3 | ) |  |  | (24.8 | ) |  |  | (6.8 | )
Income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries |  |  | 77.5 |  |  |  | 69.6 |  |  |  | 184.1 |  |  |  | 163.6 |
Income tax provision |  |  | 19.9 |  |  |  | 19.9 |  |  |  | 49.8 |  |  |  | 51.8 |
Equity in income of unconsolidated investees, net of tax |  |  | 0.2 |  |  |  | — |  |  |  | 0.9 |  |  |  | — |
Consolidated net income |  |  | 57.8 |  |  |  | 49.7 |  |  |  | 135.2 |  |  |  | 111.8 |
Net income attributable to noncontrolling interests in consolidated subsidiaries |  |  | 0.7 |  |  |  | 0.2 |  |  |  | 1.6 |  |  |  | 0.7 |
Net income attributable to Bruker Corporation |  | $ | 57.1 |  |  | $ | 49.5 |  |  | $ | 133.6 |  |  | $ | 111.1 |
Net income per common share attributable to Bruker Corporation shareholders: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.39 |  |  | $ | 0.33 |  |  | $ | 0.91 |  |  | $ | 0.74 |
Diluted |  | $ | 0.39 |  |  | $ | 0.33 |  |  | $ | 0.91 |  |  | $ | 0.74 |
Weighted average common shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 146.8 |  |  |  | 149.0 |  |  |  | 146.8 |  |  |  | 149.7 |
Diluted |  |  | 147.7 |  |  |  | 149.8 |  |  |  | 147.6 |  |  |  | 150.6 |
Comprehensive income |  | $ | 52.9 |  |  | $ | 15.9 |  |  | $ | 145.5 |  |  | $ | 69.1 |
Less: Comprehensive income (loss) attributable to noncontrolling interests |  |  | 1.3 |  |  |  | (0.4 | ) |  |  | 2.6 |  |  |  | (0.2 | )
Less: Comprehensive loss attributable to redeemable noncontrolling interests |  |  | (0.3 | ) |  |  | (0.5 | ) |  |  | (0.3 | ) |  |  | (0.7 | )
Comprehensive income attributable to Bruker Corporation |  | $ | 51.9 |  |  | $ | 16.8 |  |  | $ | 143.2 |  |  | $ | 70.0 |

The accompanying notes are an integral part of these financial statements.

4

##### Table of Contents

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS’ EQUITY

(in millions, except share data)

|  | Redeemable Noncontrolling Interests |  |  |  | Common Shares |  |  | Common Stock Amount |  |  | Treasury Shares |  |  | Treasury Stock Amount |  |  | Additional Paid-In Capital |  |  | Retained Earnings |  |  | Accumulated Other Comprehensive Income |  |  | Total Shareholders’ Equity Attributable to Bruker Corporation |  |  | Noncontrolling Interests in Consolidated Subsidiaries |  |  | Total Shareholders’ Equity |
Balance at December 31, 2022 |  | $ | 6.1 |  |  |  |  | 147,023,144 |  |  | $ | 1.7 |  |  |  | 28,366,442 |  |  | $ | (1,085.0 | ) |  | $ | 256.3 |  |  | $ | 1,926.0 |  |  | $ | 14.8 |  |  | $ | 1,113.8 |  |  | $ | 11.9 |  |  | $ | 1,125.7 |
Stock options exercised |  |  | — |  |  |  |  | 34,957 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 0.7 |  |  |  | — |  |  |  | — |  |  |  | 0.7 |  |  |  | — |  |  |  | 0.7 |
Restricted stock units vested |  |  | — |  |  |  |  | 18,463 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (0.1 | ) |  |  | — |  |  |  | — |  |  |  | (0.1 | ) |  |  | — |  |  |  | (0.1 | )
Stock-based compensation |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4.1 |  |  |  | — |  |  |  | — |  |  |  | 4.1 |  |  |  | — |  |  |  | 4.1 |
Employee stock purchase plan |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 0.2 |  |  |  | — |  |  |  | — |  |  |  | 0.2 |  |  |  | — |  |  |  | 0.2 |
Shares repurchased |  |  | — |  |  |  |  | (315,318 | ) |  |  | — |  |  |  | 315,318 |  |  |  | (22.2 | ) |  |  | (0.1 | ) |  |  | — |  |  |  | — |  |  |  | (22.3 | ) |  |  | — |  |  |  | (22.3 | )
Cash dividends paid to common shareholders ($0.05 per share) |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (7.4 | ) |  |  | — |  |  |  | (7.4 | ) |  |  | — |  |  |  | (7.4 | )
Biognosys acquisition - other shareholders |  |  | 2.3 |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Other majority owned acquisition - other shareholders |  |  | 3.6 |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Proceeds from the sale of noncontrolling interests |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 5.3 |  |  |  | 5.3 |
Consolidated net (loss) income |  |  | (0.1 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 76.5 |  |  |  | — |  |  |  | 76.5 |  |  |  | 1.0 |  |  |  | 77.5 |
Other comprehensive income |  |  | 0.1 |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 14.8 |  |  |  | 14.8 |  |  |  | 0.3 |  |  |  | 15.1 |
Balance at March 31, 2023 |  | $ | 12.0 |  |  |  |  | 146,761,246 |  |  | $ | 1.7 |  |  |  | 28,681,760 |  |  | $ | (1,107.2 | ) |  | $ | 261.1 |  |  | $ | 1,995.1 |  |  | $ | 29.6 |  |  | $ | 1,180.3 |  |  | $ | 18.5 |  |  | $ | 1,198.8 |
Stock options exercised |  |  | — |  |  |  |  | 26,265 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 0.5 |  |  |  | — |  |  |  | — |  |  |  | 0.5 |  |  |  | — |  |  |  | 0.5 |
Restricted stock units vested |  |  | — |  |  |  |  | 2,897 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Stock-based compensation |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4.1 |  |  |  | — |  |  |  | — |  |  |  | 4.1 |  |  |  | — |  |  |  | 4.1 |
Employee stock purchase plan |  |  | — |  |  |  |  | 26,667 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1.8 |  |  |  | — |  |  |  | — |  |  |  | 1.8 |  |  |  | — |  |  |  | 1.8 |
Cash dividends paid to common shareholders ($0.05 per share) |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (7.4 | ) |  |  | — |  |  |  | (7.4 | ) |  |  | — |  |  |  | (7.4 | )
Biognosys acquisition - other shareholders |  |  | 0.2 |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Loan to noncontrolling interest |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (0.3 | ) |  |  | (0.3 | )
Consolidated net (loss) income |  |  | (0.4 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 57.1 |  |  |  | — |  |  |  | 57.1 |  |  |  | 1.1 |  |  |  | 58.2 |
Other comprehensive income (loss) |  |  | 0.1 |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (5.2 | ) |  |  | (5.2 | ) |  |  | 0.2 |  |  |  | (5.0 | )
Balance at June 30, 2023 |  | $ | 11.9 |  |  |  |  | 146,817,075 |  |  | $ | 1.7 |  |  |  | 28,681,760 |  |  | $ | (1,107.2 | ) |  | $ | 267.5 |  |  | $ | 2,044.8 |  |  | $ | 24.4 |  |  | $ | 1,231.2 |  |  | $ | 19.5 |  |  | $ | 1,250.7 |

The accompanying notes are an integral part of these financial statements.

5

##### Table of Contents

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS’ EQUITY

(in millions, except share data)

|  | Redeemable Noncontrolling Interests |  |  |  | Common Shares |  |  | Common Stock Amount |  |  | Treasury Shares |  |  | Treasury Stock Amount |  |  | Additional Paid-In Capital |  |  | Retained Earnings |  |  | Accumulated Other Comprehensive Loss |  |  | Total Shareholders’ Equity Attributable to Bruker Corporation |  |  | Noncontrolling Interests in Consolidated Subsidiaries |  |  | Total Shareholders’ Equity |
Balance at December 31, 2021 |  | $ | 0.2 |  |  |  |  | 150,753,687 |  |  | $ | 1.7 |  |  |  | 24,151,348 |  |  | $ | (820.3 | ) |  | $ | 237.8 |  |  | $ | 1,659.5 |  |  | $ | (8.2 | ) |  | $ | 1,070.5 |  |  | $ | 14.1 |  |  | $ | 1,084.6 |
Stock options exercised |  |  | — |  |  |  |  | 118,630 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3.1 |  |  |  | — |  |  |  | — |  |  |  | 3.1 |  |  |  | — |  |  |  | 3.1 |
Restricted stock units vested |  |  | — |  |  |  |  | 22,440 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Stock-based compensation |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3.8 |  |  |  | — |  |  |  | — |  |  |  | 3.8 |  |  |  | — |  |  |  | 3.8 |
Shares repurchased |  |  | — |  |  |  |  | (1,603,055 | ) |  |  | — |  |  |  | 1,603,055 |  |  |  | (105.6 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (105.6 | ) |  |  | — |  |  |  | (105.6 | )
Cash dividends paid to common shareholders ($0.05 per share) |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (7.5 | ) |  |  | — |  |  |  | (7.5 | ) |  |  | — |  |  |  | (7.5 | )
Consolidated net income |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 61.6 |  |  |  | — |  |  |  | 61.6 |  |  |  | 0.5 |  |  |  | 62.1 |
PreOmics acquisition - other shareholders |  |  | 6.8 |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Other comprehensive loss |  |  | (0.2 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (8.9 | ) |  |  | (8.9 | ) |  |  | (0.3 | ) |  |  | (9.2 | )
Balance at March 31, 2022 |  | $ | 6.8 |  |  |  |  | 149,291,702 |  |  | $ | 1.7 |  |  |  | 25,754,403 |  |  | $ | (925.9 | ) |  | $ | 244.7 |  |  | $ | 1,713.6 |  |  | $ | (17.1 | ) |  | $ | 1,017.0 |  |  | $ | 14.3 |  |  | $ | 1,031.3 |
Stock options exercised |  |  | — |  |  |  |  | 14,110 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 0.2 |  |  |  | — |  |  |  | — |  |  |  | 0.2 |  |  |  | — |  |  |  | 0.2 |
Restricted stock units vested |  |  | — |  |  |  |  | 1,811 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Stock-based compensation |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3.8 |  |  |  | — |  |  |  | — |  |  |  | 3.8 |  |  |  | — |  |  |  | 3.8 |
Shares repurchased |  |  | — |  |  |  |  | (983,741 | ) |  |  | — |  |  |  | 983,741 |  |  |  | (60.3 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (60.3 | ) |  |  | — |  |  |  | (60.3 | )
Cash dividends paid to common shareholders ($0.05 per share) |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (7.5 | ) |  |  | — |  |  |  | (7.5 | ) |  |  | — |  |  |  | (7.5 | )
Consolidated net income |  |  | (0.2 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 49.5 |  |  |  | — |  |  |  | 49.5 |  |  |  | 0.4 |  |  |  | 49.9 |
Other comprehensive income (loss) |  |  | (0.3 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (32.2 | ) |  |  | (32.2 | ) |  |  | (0.8 | ) |  |  | (33.0 | )
Balance at June 30, 2022 |  | $ | 6.3 |  |  |  |  | 148,323,882 |  |  | $ | 1.7 |  |  |  | 26,738,144 |  |  | $ | (986.2 | ) |  | $ | 248.7 |  |  | $ | 1,755.6 |  |  | $ | (49.3 | ) |  | $ | 970.5 |  |  | $ | 13.9 |  |  | $ | 984.4 |

The accompanying notes are an integral part of these financial statements.

6

##### Table of Contents

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |
Cash flows from operating activities: |  |  |  |  |  |
Consolidated net income |  | $ | 135.2 |  |  | $ | 111.8 |
Adjustments to reconcile consolidated net income to cash flows from operating activities: |  |  |  |  |  |
Depreciation and amortization |  |  | 51.0 |  |  |  | 43.3 |
Stock-based compensation expense |  |  | 12.1 |  |  |  | 17.7 |
Deferred income taxes |  |  | 9.4 |  |  |  | (8.2 | )
Impairment of strategic investments and other long-lived assets |  |  | 18.3 |  |  |  | 1.9 |
Gain on sale of strategic investment |  |  | (6.8 | ) |  |  | — |
Gain on sale of property, plant and equipment |  |  | (9.6 | ) |  |  | (11.2 | )
Other non-cash expenses, net |  |  | 16.0 |  |  |  | 13.2 |
Changes in operating assets and liabilities, net of acquisitions and divestitures: |  |  |  |  |  |
Accounts receivable |  |  | 30.5 |  |  |  | (4.4 | )
Inventories |  |  | (114.4 | ) |  |  | (104.6 | )
Accounts payable and accrued expenses |  |  | (3.4 | ) |  |  | (17.3 | )
Income taxes payable, net |  |  | (17.8 | ) |  |  | (16.5 | )
Deferred revenue and customer advances |  |  | 21.1 |  |  |  | 21.2 |
Other changes in operating assets and liabilities, net |  |  | (41.1 | ) |  |  | (13.5 | )
Net cash provided by operating activities |  |  | 100.5 |  |  |  | 33.4 |
Cash flows from investing activities: |  |  |  |  |  |
Purchases of property, plant and equipment |  |  | (48.5 | ) |  |  | (36.9 | )
Maturity of short-term investments |  |  | — |  |  |  | 100.0 |
Proceeds from sale of strategic investment |  |  | 11.8 |  |  |  | — |
Cash paid for strategic investments |  |  | (9.3 | ) |  |  | (38.1 | )
Cash paid for acquisitions, net of cash acquired |  |  | (102.7 | ) |  |  | (85.4 | )
Proceeds from sales of property, plant and equipment |  |  | 10.7 |  |  |  | 13.8 |
Net proceeds from cross-currency swap agreements |  |  | 3.8 |  |  |  | 1.9 |
Net cash used in investing activities |  |  | (134.2 | ) |  |  | (44.7 | )
Cash flows from financing activities: |  |  |  |  |  |
Proceeds from long-term debt |  |  | 2.8 |  |  |  | 0.1 |
Repayment of other debt, net |  |  | (4.5 | ) |  |  | (1.0 | )
Repayment of 2012 Note Purchase Agreement |  |  | — |  |  |  | (105.0 | )
Repayment of 2019 Note Purchase Agreement |  |  | (7.5 | ) |  |  | (1.5 | )
Proceeds from issuance of common stock, net |  |  | 2.8 |  |  |  | 3.3 |
Payment of contingent consideration |  |  | (2.5 | ) |  |  | (4.8 | )
Payment of dividends to common shareholders |  |  | (14.7 | ) |  |  | (15.0 | )
Repurchase of common stock |  |  | (22.4 | ) |  |  | (165.9 | )
Proceeds from (payment for) the sale (purchase) of noncontrolling interests |  |  | 5.0 |  |  |  | (7.4 | )
Net cash used in financing activities |  |  | (41.0 | ) |  |  | (297.2 | )
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  |  | 4.2 |  |  |  | (36.9 | )
Net change in cash, cash equivalents and restricted cash |  |  | (70.5 | ) |  |  | (345.4 | )
Cash, cash equivalents and restricted cash at beginning of period |  |  | 648.7 |  |  |  | 1,071.7 |
Cash, cash equivalents and restricted cash at end of period |  | $ | 578.2 |  |  | $ | 726.3 |
Supplemental disclosure of cash flow information: |  |  |  |  |  |
Restricted cash period beginning balance |  | $ | 3.2 |  |  | $ | 3.5 |
Restricted cash period ending balance |  | $ | 3.4 |  |  | $ | 3.3 |

The accompanying notes are an integral part of these financial statements.

7

##### Table of Contents

BRUKER CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2023

1.
Description of Business

Bruker Corporation, together with its consolidated subsidiaries (Bruker or the Company), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research.

The Company has four reportable segments, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO and Bruker Energy & Supercon Technologies (BEST).

BSI BioSpin Segment designs, manufactures and distributes enabling life science tools based on magnetic resonance technology. BioSpin Segment’s revenues are generated by academic and government research customers, pharmaceutical and biotechnology companies and nonprofit laboratories, as well as chemical, food and beverage, clinical and other industrial companies.

BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection) Segment designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. Customers of the BSI CALID Segment include academic institutions and medical schools; pharmaceutical, biotechnology and diagnostics companies; contract research organizations; nonprofit and for-profit forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies.

BSI NANO Segment designs, manufactures and distributes advanced X-ray instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile X-ray fluorescence spectrometry instruments; spark optical emission spectroscopy systems; Chipcytometry products and services for targeted spatial proteomics, multi-omic services; and products and services for spatial genomics research. Customers of the BSI NANO Segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials research and life science research analysis.

BEST Segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and “big science” research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.

The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of June 30, 2023 and December 31, 2022, and for the three and six months ended June 30, 2023 and 2022, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, the financial information presented herein does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year.

At June 30, 2023, the Company’s significant accounting policies, which are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, have not changed.

8

##### Table of Contents

Risks and Uncertainties

The Company is subject to risks common to its industry including, but not limited to, global economic conditions, including increasing inflation, uncertainties caused by recent banking industry volatility, rapid technological change, government and academic funding levels, geopolitical uncertainties, changes in commodity prices, spending patterns of its customers, protection of its intellectual property, availability of key raw materials and components and other supply chain challenges, compliance with existing and future regulation by government agencies and fluctuations in foreign currency exchange rates and interest rates.

The Company has experienced supply chain interruptions as a result of general global economic conditions, including inflation and the threat of a potential recession, a tighter labor market and other factors including natural events and disasters. Various factors, including increased demand for certain components and production delays, are contributing to shortages of certain components used in the Company’s products and increased difficulties in the Company’s ability to obtain a consistent supply of materials at stable pricing levels. Supply shortages and longer lead times for components used in the Company’s products, including limited source components, has resulted and may continue to cause disruptions to the Company’s production activities, which has had and may continue to have an adverse effect on the Company’s financial condition or result of operations. These factors have impacted and may continue to impact the timing of the Company’s revenue, and have also resulted, and may in the future result in a delay of revenue, and an increase in manufacturing costs, all of which have adversely impacted and may continue to adversely impact the Company’s operating results.

Additionally, geopolitical tensions, such as Russia's incursion into and ongoing war in Ukraine, ongoing conflicts between the United States and China, tariff and trade policy changes, economic sanctions, and increasing potential of conflict involving countries in Asia that are critical to the Company's supply chain operations, such as Taiwan and China, have resulted in increasing global instability and create uncertainty for global commerce. In addition to experiencing adverse economic impacts resulting from economic sanctions on Russia, as well as the prospect of a reduction in natural gas exports from Russia and resulting market disruptions, such as higher prices for and reduced availability of key metals used in our products, the Company has ceased its Russian operations. Sustained or worsening global economic conditions and increasing inflation and geopolitical tensions have increased the Company's cost of doing business, impacted the Company's supply chain operations, caused some of the Company's customers to reduce or delay spending and further intensified pricing pressures. Combined with increased inflation, potential energy shortages in Europe where we have significant operations and overall higher energy and transportation costs, these factors have affected and may continue to affect the Company's financial condition and result of operations.

The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the global supply chain interruptions, higher energy costs and shortages, the global economy, including inflation and the threat of recession, and geopolitical instability will directly or indirectly impact future business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee cost related amounts, will depend on future developments that are highly uncertain, including as a result of new developments concerning global supply chain and various global conflicts. The Company has made estimates of the impact of these disruptions within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management’s estimates if these results differ from historical experience.

Deferred revenue previously included in other current liabilities on the consolidated balance sheets is currently presented together with customer advances. The change in the prior period was made to conform to the current period presentation.

9

##### Table of Contents

2.
Recent Accounting Pronouncements

In March 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-01, Leases (Topic 842): Common Control Arrangements (“ASU 2023-01”), which provides additional guidance concerning related party leasing arrangements between entities under common control. Specifically, ASU 2023-01 provides new guidance for all entities on the amortization period of leasehold improvements for common control arrangements. This guidance is effective for annual and interim reporting periods beginning after December 15, 2023. The adoption of this ASU in 2023 has not had a material impact on the Company's consolidated financial statements.

3.
Revenue

The following tables present the Company’s revenues by Segment and End Customer Geography (in millions):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Revenue by Segment: |  |  |  |  |  |  |  |  |  |  |  |
BSI BioSpin |  | $ | 162.0 |  |  | $ | 159.8 |  |  | $ | 342.3 |  |  | $ | 317.6 |
BSI CALID |  |  | 227.2 |  |  |  | 190.3 |  |  |  | 463.9 |  |  |  | 393.5 |
BSI NANO |  |  | 225.1 |  |  |  | 182.2 |  |  |  | 434.7 |  |  |  | 360.7 |
BEST |  |  | 72.7 |  |  |  | 59.2 |  |  |  | 134.9 |  |  |  | 118.9 |
Eliminations (a) |  |  | (5.1 | ) |  |  | (3.1 | ) |  |  | (8.6 | ) |  |  | (7.3 | )
Total revenue |  | $ | 681.9 |  |  | $ | 588.4 |  |  | $ | 1,367.2 |  |  | $ | 1,183.4 |

(a)
Represents corporate costs and eliminations not allocated to the reportable segments.

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Revenue by End Customer Geography: |  |  |  |  |  |  |  |  |  |  |  |
United States |  | $ | 179.3 |  |  | $ | 171.5 |  |  | $ | 354.4 |  |  | $ | 326.5 |
Germany |  |  | 61.5 |  |  |  | 67.3 |  |  |  | 124.1 |  |  |  | 125.8 |
Rest of Europe |  |  | 161.2 |  |  |  | 130.3 |  |  |  | 321.0 |  |  |  | 273.7 |
China |  |  | 116.5 |  |  |  | 93.1 |  |  |  | 224.1 |  |  |  | 179.4 |
Rest of Asia Pacific |  |  | 106.8 |  |  |  | 83.4 |  |  |  | 239.4 |  |  |  | 186.0 |
Other |  |  | 56.6 |  |  |  | 42.8 |  |  |  | 104.2 |  |  |  | 92.0 |
Total revenue |  | $ | 681.9 |  |  | $ | 588.4 |  |  | $ | 1,367.2 |  |  | $ | 1,183.4 |

Revenue for the Company recognized at a point in time versus over time is as follows (in millions):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Revenue recognized at a point in time |  | $ | 586.7 |  |  | $ | 509.2 |  |  | $ | 1,185.4 |  |  | $ | 1,023.2 |
Revenue recognized over time |  |  | 95.2 |  |  |  | 79.2 |  |  |  | 181.8 |  |  |  | 160.2 |
Total revenue |  | $ | 681.9 |  |  | $ | 588.4 |  |  | $ | 1,367.2 |  |  | $ | 1,183.4 |

Remaining Performance Obligations

Remaining performance obligations represent the aggregate transaction price allocated to a promise to transfer a good or service that is fully or partially unsatisfied at the end of the period. As of June 30, 2023, remaining performance obligations were approximately $2,339.4 million.

10

##### Table of Contents

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, note receivables and unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Company’s unaudited condensed consolidated balance sheets.

Contract assets—Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Billing often occurs subsequent to revenue recognition, resulting in contract assets. Contract assets are generally classified as other current assets in the unaudited condensed consolidated balance sheets. The balance of contract assets as of June 30, 2023 and December 31, 2022 was $76.4 million and $61.3 million, respectively.

Contract liabilities—The Company often receives cash payments from customers in advance of the Company’s performance, resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the unaudited condensed consolidated balance sheets based on the timing of when revenue recognition is expected. As of June 30, 2023 and December 31, 2022, the contract liabilities were $498.3 million and $471.7 million, respectively. The increase in the contract liability balance during the six months ended June 30, 2023 is primarily the result of new cash payments received, which was offset in part by satisfying performance obligations. Approximately $242.6 million of the contract liability balance on December 31, 2022 was recognized as revenue during the six months ended June 30, 2023.

4.
Other Current Assets

Other current assets consisted of the following (in millions):

|  | June 30, 2023 |  |  | December 31, 2022 |
Unbilled and notes receivable |  | $ | 75.7 |  |  | $ | 60.8 |
Income and other taxes receivable |  |  | 75.9 |  |  |  | 61.8 |
Prepaid expenses |  |  | 36.4 |  |  |  | 24.3 |
Other current assets |  |  | 55.1 |  |  |  | 46.6 |
Other current assets |  | $ | 243.1 |  |  | $ | 193.5 |

5.
Acquisitions

The Company has not presented pro forma financial information reflecting all acquisitions because the impact, individually and collectively, on revenues and net income is not material. The Company does not expect the amounts allocated to goodwill that are attributable to expected synergies to be deductible for tax purposes.

2023

Biognosys, AG

On January 3, 2023, the Company acquired 97.15% of the outstanding stock of Biognosys, AG (“Biognosys”), a privately held company, for a purchase price of CHF 75 million (approximately $80.1 million) less assumed liability for employee awards of CHF 5.9 million (approximately $6.3 million). Biognosys offers mass spectrometry based next-generation proteomics contract research services as well as proprietary proteomics software and laboratory consumables to support academic, pharma and biotech research and clinical development. Biognosys is domiciled in Zurich, Switzerland, and was integrated into the BSI CALID Segment.

Concurrent with the acquisition, the Company entered into an agreement with the noncontrolling interest holders that provides the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 2.85% of Biognosys for cash to the founders at a contractually defined redemption value exercisable beginning in 2028. The option price to acquire the remaining 2.85% equity interest will have a minimum redemption, or floor, value at each purchase or sell date, subject to post combination employment. The fair value at acquisition date of these put option rights has been bifurcated into two financial instruments to separately account for the amounts attributable to the put option rights to sell the non-controlling interests on exercise dates at (1) above the minimum redemption value and (2) the minimum redemption value or floor value that is subject to post combination employment (the hybrid instrument) services.

11

##### Table of Contents

The rights (embedded derivative) to the option shares can be sold at a minimum redemption value provided certain post combination employment services are met or at fair value, if above the floor, on the purchase or sell date. Therefore, the portion assigned to the minimum redemption value of option value of the hybrid instrument, which is tied to continued employment of the noncontrolling interest holders, was classified as a long-term liability on the consolidated balance sheet. The hybrid instrument was initially measured at fair value on the acquisition date and shall be accreted over the post combination service period. The acquisition date fair value of the hybrid instrument which is an embedded derivative was not material.

The rights associated with the portion of the noncontrolling interest above the minimum redemption value are contingently redeemable at the option of the Company or the noncontrolling interest holders. As redemption of the rights is contingently redeemable at the option of the noncontrolling interest shareholders, the Company classifies the carrying amount of these rights in the mezzanine section on the consolidated balance sheet, which is presented above the equity section and below liabilities. The redeemable noncontrolling interest is initially measured at fair value on acquisition date and subsequently at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on fair value as defined in the purchase agreement and its carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. Adjustments to the carrying value of the redeemable noncontrolling interest are recorded through retained earnings.

The amortization period for the intangible assets acquired is seven years for the technology and nine years for the customer relationships. The trade name was determined to have an indefinite life. The Company expects to amortize backlog through the end of 2025.

The components and fair value allocation of the consideration transferred in connection with the acquisition are as follows (in millions):

Consideration Transferred: |  |  |
Cash paid |  | $ | 73.6 |
Cash acquired |  |  | (9.5 | )
Holdback |  |  | 0.2 |
Fair value of redeemable noncontrolling interest |  |  | 2.5 |
Total consideration transferred |  | $ | 66.8 |
Allocation of Consideration Transferred: |  |  |
Accounts receivable |  | $ | 3.6 |
Inventories |  |  | 0.4 |
Other current assets |  |  | 0.9 |
Property, plant and equipment |  |  | 8.0 |
Other assets |  |  | 4.2 |
Intangible assets: |  |  |
Technology |  |  | 10.2 |
Customer relationships |  |  | 13.8 |
Trade name |  |  | 2.7 |
Backlog |  |  | 0.8 |
Goodwill |  |  | 47.7 |
Liabilities assumed (a) |  |  | (25.5 | )
Total consideration allocated |  | $ | 66.8 |

(a) This amount includes assumed liability for employee awards of $6.3 million on acquisition date and was settled in the post-closing period ended March 31, 2023.

Zontal, Inc.

On May 4, 2023, the Company acquired 60% of the outstanding share capital of OSTHUS Beteiligungs GmbH and its wholly-owned subsidiaries: Osthus Group GmbH, Zontal Inc., Zontal GmbH, and Zontal Data Information Technology (Dalian) co., Ltd, (hereinafter, the “Zontal Companies”) for EUR 13.4 million (approximately $14.8 million) with the potential for additional consideration of up to $14.4 million if certain revenue and EBITDA targets are met through 2025. Zontal, Inc, is the main operating company. The Zontal Companies offer various software applications and integrations included data management (Informatics and SDMS), which enables customers to harmonize, preserve and reuse their data to generate efficiencies and automate workflows. The Zontal Companies are domiciled in Aachen, Germany, and are integrated into the BSI BioSpin Segment.

12

##### Table of Contents

Concurrent with the acquisition, the Company entered into an agreement with the noncontrolling interest holders that provides the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 40% of the Zontal Companies at a contractually defined redemption value exercisable beginning in 2027 and in 2031. The rights (embedded derivative) to the option shares can be exercised at a discounted redemption value upon certain events related to post combination employment services. As the options are tied to continued employment, the Company classified the hybrid instrument (noncontrolling interest with an embedded derivative) as a long-term liability on the consolidated balance sheet. The hybrid instrument associated with the options is initially measured at fair value on the acquisition date. Subsequent to the acquisition, the carrying value of the hybrid instrument is remeasured to fair value with changes recorded to stock-based compensation expense in proportion to the requisite service period vested.

The amortization period for the intangible assets acquired is eight years for technology, ten years for the trade name, and thirteen years for the customer relationships. The Company expects to amortize backlog through 2023.

The components and fair value allocation of the consideration transferred in connection with the acquisition are as follows (in millions):

Consideration Transferred: |  |  |
Cash paid |  | $ | 14.8 |
Cash acquired |  |  | (0.2 | )
Fair value of contingent consideration |  |  | 0.5 |
Fair value of hybrid liability |  |  | 18.5 |
Total consideration transferred |  | $ | 33.6 |
Allocation of Consideration Transferred: |  |  |
Accounts receivable |  | $ | 0.7 |
Other current assets |  |  | 0.3 |
Other assets |  |  | 1.2 |
Intangible assets: |  |  |
Technology |  |  | 5.8 |
Customer relationships |  |  | 4.0 |
Trade name |  |  | 1.1 |
Backlog |  |  | 0.2 |
Goodwill |  |  | 27.4 |
Liabilities assumed |  |  | (7.1 | )
Total consideration allocated |  | $ | 33.6 |

In the six months ended June 30, 2023, the Company acquired various other businesses which were accounted for under the acquisition method that complemented the Company’s existing product offerings. The following table reflects the consideration transferred and the respective reporting segment for the acquisitions (in millions):

Name of Acquisition |  | Date Acquired |  | Segment |  | Total Consideration |  |  | Cash Consideration |
Acquifer Imaging GmbH and Deltabyte GmbH |  | January 4, 2023 |  | BSI NANO |  | $ | 7.6 |  |  | $ | 7.6 |
Other majority owned acquisitions |  | Various |  | BSI CALID |  |  | 19.1 |  |  |  | 12.2 |
|  |  |  |  |  | $ | 26.7 |  |  | $ | 19.8 |

In the six months ended June 30, 2023, the Company completed strategic investments that complemented the Company's existing product offerings. The following table reflects the consideration transferred and the respective reporting segment for the investments (in millions):

Name |  | Acquisition / Investment |  | Financial Statement Classification |  | Date Acquired |  | Segment |  | Total Consideration |  |  | Cash Consideration |
Other Investments |  | Investment |  | Other long-term assets |  | Various |  | Various |  | $ | 9.2 |  |  | $ | 9.2 |
|  |  |  |  |  |  |  |  |  | $ | 9.2 |  |  | $ | 9.2 |

In the three and six months ended June 30, 2023, the Company recorded a realized gain of $6.8 million from the sale of a strategic investment. In the six months ended June 30, 2022, the Company recorded an unrealized gain of $1.7 million from the remeasurement of a strategic investment upon the occurrence of an observable transaction. The realized and unrealized gain is included in “Interest and other income (expense), net” in the Consolidated Statements of Income and Comprehensive Income.

13

##### Table of Contents

Equity-method investments

The Company's investment in Tofwerk, AG and Eliptica Limited amount to an equity investment in common stock of 40% and 20%, respectively, and are accounted for using the equity-method of accounting. The Company accounts for the investments under the equity method if the Company has the ability to exercise significant influence, but not control, over an investee. Investments in equity-method investees are included within “Other long-term assets” in the consolidated balance sheets. The Company's proportional share of the earnings or losses as reported by equity-method investees are classified as “Equity in income of unconsolidated investees, net of tax” in the consolidated statements of income and comprehensive income. The Company regularly evaluates these investments, which are not carried at fair value, for other-than-temporary impairment. The Company records investments, including incremental investments, of shares in equity-method investees at cost. In the event the Company no longer has the ability to exercise significant influence over an equity-method investee, the Company would discontinue accounting for the investment under the equity method.

On a quarterly basis, the Company reviews strategic investments and equity method investments to determine if there have been any events and conditions that could indicate an impairment or other-than temporary impairment. For the three months ended June 30, 2023, the Company recognized a $11.4 million impairment charge in “Interest and other income (expense), net” in the Consolidated Statements of Income and Comprehensive Income, to write down the carrying value of certain strategic investments. For the six months ended June 30, 2023, the Company recognized a $18.3 million impairment charge in “Interest and other income (expense), net” in the Consolidated Statements of Income and Comprehensive Income, to write down the carrying value of certain strategic investments.

Subsequent Events - Acquisitions

On July 26, 2023, the Company acquired a 3.28% diluted equity interest in Tome Biosciences Inc. for $10.0 million.

6.
Inventories

Inventories consisted of the following (in millions):

|  | June 30, 2023 |  |  | December 31, 2022 |
Raw materials |  | $ | 333.2 |  |  | $ | 300.9 |
Work-in-process |  |  | 322.7 |  |  |  | 278.7 |
Finished goods |  |  | 154.5 |  |  |  | 128.2 |
Demonstration units |  |  | 104.2 |  |  |  | 92.3 |
Total Inventories |  | $ | 914.6 |  |  | $ | 800.1 |

Finished goods include in-transit systems shipped to the Company’s customers for which control has not passed to the customers. As of June 30, 2023, and December 31, 2022, the value of inventory-in-transit was $45.5 million and $41.1 million, respectively.

7.
Goodwill and Intangible Assets

Goodwill

The following table sets forth the changes in the carrying amount of goodwill (in millions):

Balance at December 31, 2022 |  | $ | 457.6 |
Current period additions/adjustments |  |  | 92.4 |
Foreign currency effect |  |  | 7.9 |
Balance at June 30, 2023 |  | $ | 557.9 |

14

##### Table of Contents

Intangible Assets

The following is a summary of intangible assets (in millions):

|  | June 30, 2023 |  |  | December 31, 2022 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |
Existing technology and related patents |  | $ | 380.3 |  |  | $ | (232.8 | ) |  | $ | 147.5 |  |  | $ | 354.7 |  |  | $ | (219.0 | ) |  | $ | 135.7 |
Customer relationships |  |  | 216.0 |  |  |  | (82.4 | ) |  |  | 133.6 |  |  |  | 192.3 |  |  |  | (72.1 | ) |  |  | 120.2 |
Trade names |  |  | 27.1 |  |  |  | (8.4 | ) |  |  | 18.7 |  |  |  | 22.3 |  |  |  | (7.4 | ) |  |  | 14.9 |
Other |  |  | 2.1 |  |  |  | (1.5 | ) |  |  | 0.6 |  |  |  | 1.0 |  |  |  | (0.9 | ) |  |  | 0.1 |
Intangible assets |  | $ | 625.5 |  |  | $ | (325.1 | ) |  | $ | 300.4 |  |  | $ | 570.3 |  |  | $ | (299.4 | ) |  | $ | 270.9 |

For the three months ended June 30, 2023 and 2022, the Company recorded amortization expense of $11.2 million and $9.4 million, respectively, related to intangible assets subject to amortization. For the six months ended June 30, 2023 and 2022, the Company recorded amortization expense of $21.9 million and $18.6 million, respectively, related to intangible assets subject to amortization.

On a quarterly basis, the Company reviews its goodwill and intangible assets to determine if there have been any triggering events that could indicate an impairment. There were no events noted for the six months ended June 30, 2023 or 2022.

8.
Debt

The Company’s debt obligations consist of the following (in millions):

|  | June 30, 2023 |  |  | December 31, 2022 |
EUR notes (in U.S. Dollars) under the 2021 Note Purchase Agreement |  | $ | 163.8 |  |  | $ | 160.6 |
CHF notes (in U.S. Dollars) under the 2021 Note Purchase Agreement |  |  | 335.4 |  |  |  | 325.1 |
CHF notes (in U.S. Dollars) under the 2019 Note Purchase Agreement |  |  | 332.0 |  |  |  | 321.9 |
U.S. Dollar notes under the 2019 Term Loan Agreement |  |  | 285.8 |  |  |  | 293.3 |
U.S. Dollar notes under the 2012 Note Purchase Agreement |  |  | 100.0 |  |  |  | 100.0 |
Unamortized debt issuance costs |  |  | (1.5 | ) |  |  | (1.7 | )
Other loans |  |  | 7.8 |  |  |  | 5.9 |
Total notes and loans outstanding |  |  | 1,223.3 |  |  |  | 1,205.1 |
Finance lease obligations |  |  | 20.1 |  |  |  | 14.1 |
Total debt |  |  | 1,243.4 |  |  |  | 1,219.2 |
Current portion of long-term debt and finance lease obligations |  |  | (120.9 | ) |  |  | (18.7 | )
Total long-term debt, less current portion |  | $ | 1,122.5 |  |  | $ | 1,200.5 |

The following is a summary of the maximum commitments and the net amounts available to the Company under the 2019 Revolving Credit Agreement and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at June 30, 2023 (in millions):

|  | Weighted Average Interest Rate |  | Total Amount Committed by Lenders |  |  | Outstanding Borrowings |  |  | Outstanding Letters of Credit |  |  | Total Amount Available |
2019 Credit Agreement |  | 0.15% |  | $ | 600.0 |  |  | $ | — |  |  | $ | 0.4 |  |  | $ | 599.6 |
Bank guarantees and working capital line |  | varies |  |  | 140.4 |  |  |  | — |  |  |  | 140.4 |  |  |  | — |
Total revolving lines of credit |  |  |  | $ | 740.4 |  |  | $ | — |  |  | $ | 140.8 |  |  | $ | 599.6 |

As of June 30, 2023, the Company was in compliance with the financial covenants of all debt agreements.

15

##### Table of Contents

As of June 30, 2023, the Company had several cross-currency and interest rate swap agreements with a notional value of $142.9 million of U.S. dollar to Swiss Franc and a notional value o f $242.9 million of U.S. dollar to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of our Euro and Swiss Franc denominated net asset investments. These agreements qualify for hedge accounting and accordingly the changes in fair value of the derivative are recorded in other comprehensive income and remain in accumulated comprehensive income (loss) attributable to Bruker Corporation in shareholders’ equity until the sale or substantial liquidation of the foreign operation. The difference between the interest rate received and paid under the interest rate and cross-currency swap agreements is recorded in interest and other income (expense), net in the consolidated statements of income and comprehensive income. The Company presents the cross-currency swap periodic settlements in investing activities and the interest rate swap periodic settlements in operating activities in the statement of cash flows.

On September 30, 2022, the Company entered into the Second Amendment to the 2019 Term Loan Agreement and the Second Amendment to the 2019 Credit Agreement (collectively, the “Amendments”), to modify certain aspects of the 2019 Term Loan Agreement and 2019 Credit Agreement, respectively. The Amendments modify the reference rate thereunder from London Interbank Offered Rate (“LIBOR”) to Secured Overnight Financing Rate (“SOFR”). There were no other changes to the 2019 Term Loan Agreement or 2019 Credit Agreement as a result of the Amendments. The Company did not record any gains or losses on the conversion of the reference rate for borrowings under the Term Loan Agreement from LIBOR to SOFR.

On June 16, 2022, the Company entered into the First Amendment to the 2019 Credit Agreement to modify certain contract definitions within the agreement. Primarily, the current LIBOR rates were changed to new alternative base rates for the respective currencies. As part of the change any related items, such as fall-back rates and day conventions were also changed. No other material terms were modified with this agreement. During 2022, the Company adopted the practical expedient for Reference Rate Reform related to its debt arrangements and as such, this amendment is treated as a continuation of the existing debt agreement and no gain or loss on the modification was recorded.

16

##### Table of Contents

9.
Fair Value of Financial Instruments

The Company measures the following financial assets and liabilities at fair value on a recurring basis. The following tables set forth the Company’s financial instruments measured at fair value on a recurring basis and present them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement (in millions):

June 30, 2023 |  | Total |  |  | Quoted Prices in Active Markets Available (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Time deposits and money market funds |  | $ | 291.6 |  |  | $ | — |  |  | $ | 291.6 |  |  | $ | — |
Interest rate and cross-currency swap agreements |  |  | 32.5 |  |  |  | — |  |  |  | 32.5 |  |  |  | — |
Forward currency contracts |  |  | 0.1 |  |  |  | — |  |  |  | 0.1 |  |  |  | — |
Embedded derivatives in purchase and delivery contracts |  |  | 0.8 |  |  |  | — |  |  |  | 0.8 |  |  |  | — |
Debt securities available for sale |  |  | 1.2 |  |  |  | — |  |  |  | — |  |  |  | 1.2 |
Total assets recorded at fair value |  | $ | 326.2 |  |  | $ | — |  |  | $ | 325.0 |  |  | $ | 1.2 |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  | $ | 7.5 |  |  | $ | — |  |  | $ | — |  |  | $ | 7.5 |
Hybrid instruments liability |  |  | 57.5 |  |  |  | — |  |  |  | — |  |  |  | 57.5 |
Liability awards |  |  | 1.3 |  |  |  | — |  |  |  | — |  |  |  | 1.3 |
Interest rate and cross-currency swap agreements |  |  | 18.1 |  |  |  | — |  |  |  | 18.1 |  |  |  | — |
Forward currency contracts |  |  | 1.1 |  |  |  | — |  |  |  | 1.1 |  |  |  | — |
Fixed price commodity contracts |  |  | 0.1 |  |  |  | — |  |  |  | 0.1 |  |  |  | — |
Total liabilities recorded at fair value |  | $ | 85.6 |  |  | $ | — |  |  | $ | 19.3 |  |  | $ | 66.3 |
December 31, 2022 |  | Total |  |  | Quoted Prices in Active Markets Available (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Time deposits and money market funds |  | $ | 198.7 |  |  | $ | 34.0 |  |  | $ | 164.7 |  |  | $ | — |
Interest rate and cross-currency swap agreements |  |  | 37.8 |  |  |  | — |  |  |  | 37.8 |  |  |  | — |
Forward currency contracts |  |  | 0.6 |  |  |  | — |  |  |  | 0.6 |  |  |  | — |
Embedded derivatives in purchase and delivery contracts |  |  | 0.1 |  |  |  | — |  |  |  | 0.1 |  |  |  | — |
Fixed price commodity contracts |  |  | 0.6 |  |  |  | — |  |  |  | 0.6 |  |  |  | — |
Debt securities available for sale |  |  | 10.5 |  |  |  | — |  |  |  | — |  |  |  | 10.5 |
Total assets recorded at fair value |  | $ | 248.3 |  |  | $ | 34.0 |  |  | $ | 203.8 |  |  | $ | 10.5 |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  | $ | 9.6 |  |  | $ | — |  |  | $ | — |  |  | $ | 9.6 |
Hybrid instruments liability |  |  | 34.2 |  |  |  | — |  |  |  | — |  |  |  | 34.2 |
Liability awards |  |  | 1.1 |  |  |  | — |  |  |  | — |  |  |  | 1.1 |
Interest rate and cross-currency swap agreements |  |  | 12.2 |  |  |  | — |  |  |  | 12.2 |  |  |  | — |
Forward currency contracts |  |  | 0.3 |  |  |  | — |  |  |  | 0.3 |  |  |  | — |
Total liabilities recorded at fair value |  | $ | 57.4 |  |  | $ | — |  |  | $ | 12.5 |  |  | $ | 44.9 |

Derivative financial instruments are classified within Level 2 because there is not an active market for each derivative contract. However, the inputs used to calculate the value of the instruments are obtained from active markets.

The Company measures certain assets and liabilities at fair value with changes in fair value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to remeasure any of its existing financial assets or liabilities and did not elect the fair value option for any financial assets or liabilities which originated during the six months ended June 30, 2023 or the year ended December 31, 2022.

17

##### Table of Contents

The fair value of the Company's long-term fixed interest rate debt was $803.7 million and $767.8 million as of June 30, 2023, and December 31, 2022, respectively. The fair value was based on market and observable sources with similar maturity dates and classified as Level 2 within the fair value hierarchy. The carrying value of the Company's variable rate debt approximates its fair value at June 30, 2023 and December 31, 2022.

On a quarterly basis, the Company reviews its short-term investments to determine if there have been any events that could indicate an impairment. There were none noted for the six months ended June 30, 2023 or 2022.

Debt securities consist of investments in redeemable preferred stock. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value.

Contingent consideration recorded within other current and other long-term liabilities represents the estimated fair value of future payments to the former shareholders as part of certain acquisitions. The contingent consideration is primarily based on the applicable acquired company achieving annual revenue and gross margin targets in certain years as specified in the relevant purchase and sale agreement. The Company initially values the contingent consideration on the acquisition date by using a Monte Carlo simulation or an income approach method. The Monte Carlo method models future revenue and costs of goods sold projections and discounts the average results to present value. The income approach method involves calculating the earnout payment based on the forecasted cash flows, adjusting the future earnout payment for the risk of reaching the projected financials, and then discounting the future payments to present value by the counterparty risk. The counterparty risk considers the risk of the buyer having the cash to make the earnout payments and is commensurate with a cost of debt over an appropriate term. Changes in fair value subsequent to acquisition are recognized in “Acquisition-related expenses, net” included in Other Charges, net, in the Consolidated Statements of Income and Comprehensive Income.

The following table sets forth the changes in contingent consideration liabilities (in millions):

Balance at December 31, 2022 |  | $ | 9.6 |
Current period additions |  |  | 2.8 |
Current period adjustments |  |  | 1.2 |
Current period settlements |  |  | (6.3 | )
Foreign currency effect |  |  | 0.2 |
Balance at June 30, 2023 |  | $ | 7.5 |

As part of the 2018 Mestrelab Research, S.L. (“Mestrelab”), 2022 PreOmics, 2023 Biognosys and Zontal acquisitions and a majority owned acquisition, the Company entered into agreements with the noncontrolling interest holders that provide the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining ownerships for cash at contractually defined redemption values. These rights (embedded derivatives) can be adjusted upon certain events related to post combination employment services. As the options are tied to continued employment, the Company classified the hybrid instruments (noncontrolling interests with embedded derivatives) as long-term liabilities on the consolidated balance sheet. Subsequent to the acquisitions, the carrying value of the hybrid instruments are remeasured to fair value with changes recorded to stock-based compensation expense in proportion to the respective requisite service period vested. The Company classified the hybrid instruments as Level 3 in the fair value hierarchy.

The following table sets forth the changes in hybrid instruments liability (in millions):

Balance at December 31, 2022 |  | $ | 34.2 |
Acquisitions |  |  | 20.7 |
Current period adjustments |  |  | 1.8 |
Foreign currency effect |  |  | 0.8 |
Balance at June 30, 2023 |  | $ | 57.5 |

18

##### Table of Contents

10.
Derivative Instruments and Hedging Activities

Commodity Price Risk Management

The Company has arrangements with certain customers under which it has a firm commitment to deliver copper-based superconductors at a fixed price. In order to minimize the volatility that fluctuations in the price of copper have on the Company’s sales of these commodities, the Company enters into commodity hedge contracts. As commodity contracts settle, gains (losses) as a result of changes in fair values are adjusted to the contracts with the customers through revenues.

Foreign Exchange Rate Risk Management

The Company had the following notional amounts outstanding under foreign exchange contracts, cross-currency interest rate swap agreements and long-term debt designated as net investment hedges and the respective fair value of the financial instruments recorded in the consolidated balance sheets as follows (in millions):

|  | June 30, 2023 |  |  | December 31, 2022 |
|  | Notional (in USD) |  |  | Fair Value |  |  | Notional (in USD) |  |  | Fair Value |
Financial instruments designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  |  |
Interest rate cross-currency swap agreements |  |  |  |  |  |  |  |  |  |  |  |
Other current assets |  |  |  |  | $ | 16.9 |  |  |  |  |  | $ | 14.8 |
Other assets |  |  |  |  |  | 15.6 |  |  |  |  |  |  | 23.0 |
Other long-term liabilities |  |  |  |  |  | (18.1 | ) |  |  |  |  |  | (12.2 | )
|  | $ | 385.8 |  |  | $ | 14.4 |  |  | $ | 393.3 |  |  | $ | 25.6 |
Long-term debt |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt |  |  | 831.2 |  |  |  | (40.5 | ) |  |  | 807.6 |  |  |  | (17.0 | )
Total financial instruments designated as hedging instruments |  | $ | 1,217.0 |  |  | $ | (26.1 | ) |  | $ | 1,200.9 |  |  | $ | 8.6 |
Financial instruments not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  |  |
Forward currency contracts |  |  |  |  |  |  |  |  |  |  |  |
Other current assets |  | $ | 27.3 |  |  | $ | 0.1 |  |  | $ | 89.8 |  |  | $ | 0.6 |
Other current liabilities |  |  | 239.7 |  |  |  | (1.1 | ) |  |  | 97.4 |  |  |  | (0.3 | )
Embedded derivatives in purchase and delivery contracts |  |  |  |  |  |  |  |  |  |  |  |
Other current assets |  |  | 25.9 |  |  |  | 0.8 |  |  |  | 15.3 |  |  |  | 0.1 |
Fixed price commodity contracts |  |  |  |  |  |  |  |  |  |  |  |
Other current assets |  |  | — |  |  |  | — |  |  |  | 8.9 |  |  |  | 0.6 |
Other current liabilities |  |  | 10.5 |  |  |  | (0.1 | ) |  |  | — |  |  |  | — |
Total financial instruments not designated as hedging instruments |  | $ | 303.4 |  |  | $ | (0.3 | ) |  | $ | 211.4 |  |  | $ | 1.0 |
Total financial instruments |  | $ | 1,520.4 |  |  | $ | (26.4 | ) |  | $ | 1,412.3 |  |  | $ | 9.6 |

In addition, the Company periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. The Company accounts for these transactions separately valuing the “embedded derivative” component of these contracts. The contracts, denominated in currencies other than the functional currency of the transacting parties, amounted to $3.5 million for the delivery of products and $22.4 million for the purchase of products at June 30, 2023 and $15.3 million for the purchase of products at December 31, 2022. The Company records the changes in the fair value of these embedded derivatives in interest and other income (expense), net in the consolidated statements of income and comprehensive income.

19

##### Table of Contents

The following is a summary of the gain (loss) included in the consolidated statements of income and comprehensive income related to the financial instruments described above (in millions):

|  |  |  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | Financial Statement Classification |  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Financial instruments not designated as hedging instruments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Forward currency contracts |  | Interest and other income (expense), net |  | $ | 1.4 |  |  | $ | (2.6 | ) |  | $ | 1.3 |  |  | $ | (4.1 | )
Embedded derivatives in purchase and delivery contracts |  | Interest and other income (expense), net |  |  | 0.4 |  |  |  | 0.1 |  |  |  | 0.7 |  |  |  | — |
|  |  |  |  | 1.8 |  |  |  | (2.5 | ) |  |  | 2.0 |  |  |  | (4.1 | )
Financial instruments designated as cash flow hedging instruments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate cross-currency swap agreements |  | Interest and other income (expense), net |  | $ | 2.6 |  |  | $ | (0.6 | ) |  | $ | 4.9 |  |  | $ | (1.6 | )
Financial instruments designated as net investment hedging instruments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate cross-currency swap agreements |  | Interest and other income (expense), net |  |  | 2.0 |  |  |  | 2.2 |  |  |  | 4.0 |  |  |  | 4.3 |
|  |  |  |  | 4.6 |  |  |  | 1.6 |  |  |  | 8.9 |  |  |  | 2.7 |
Total |  |  |  | $ | 6.4 |  |  | $ | (0.9 | ) |  | $ | 10.9 |  |  | $ | (1.4 | )
|  |  |  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | Financial Statement Classification |  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Financial instruments designated as cash flow hedging instruments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate cross-currency swap agreements |  | Accumulated other comprehensive income, net of tax |  | $ | 3.0 |  |  | $ | 3.7 |  |  | $ | (0.4 | ) |  | $ | 15.1 |
|  |  |  |  | 3.0 |  |  |  | 3.7 |  |  |  | (0.4 | ) |  |  | 15.1 |
Financial instruments designated as net investment hedging instruments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate cross-currency swap agreements |  | Accumulated other comprehensive income, net of tax |  | $ | (7.1 | ) |  | $ | 14.3 |  |  | $ | (8.3 | ) |  | $ | 15.0 |
Long-term debt |  | Accumulated other comprehensive income, net of tax |  |  | (11.8 | ) |  |  | 23.5 |  |  |  | (17.9 | ) |  |  | 32.5 |
|  |  |  |  | (18.9 | ) |  |  | 37.8 |  |  |  | (26.2 | ) |  |  | 47.5 |
Total |  |  |  | $ | (15.9 | ) |  | $ | 41.5 |  |  | $ | (26.6 | ) |  | $ | 62.6 |

11.
Provision for Income Taxes

The Company accounts for income taxes using the asset and liability approach by recognizing deferred tax assets and liabilities for the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. In addition, the Company accounts for uncertain tax positions that have reached a minimum recognition threshold.

The income tax provision for both the three months ended June 30, 2023 and 2022 was $19.9 million, representing effective tax rates of 25.7% and 28.6%, respectively. The income tax provision for the six months ended June 30, 2023 and 2022 was $49.8 million and $51.8 million, respectively, representing effective tax rates of 27.1% and 31.7%, respectively. The decrease in our effective tax rate was primarily due to the impact of final treasury regulations that became effective in the fourth quarter of 2022 allowing a larger benefit relating to foreign tax credits, change in jurisdictional mix, and the impact of resolution of a tax controversy in the first quarter of 2022.

As of June 30, 2023 and December 31, 2022, the Company had gross unrecognized tax benefits, excluding penalties and interest, of approximately $59.0 million and $54.9 million, respectively, which, if recognized, would result in a reduction of the Company’s effective tax rate. The Company recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of June 30, 2023 and December 31, 2022, approx imately $4.9 million and $4.2 million, respectively, of accrued interest and penalties related to uncertain tax positions were included in other long-term liabilities on the Company’s unaudited condensed consolidated balance sheets. Penalties and interest of $0.2 million and $0.2 million were recorded in the provision for income taxes for unrecognized tax benefits during the three months ended June 30, 2023 and 2022 respectively. Penalties and interest of $0.6 million and $0.7 million were recorded in the provision for income taxes for unrecognized tax benefits during the six months ended June 30, 2023 and 2022, respectively.

20

##### Table of Contents

The Company files tax returns in the United States, which include federal, state and local jurisdictions, and many foreign jurisdictions with varying statutes of limitations. The Company considers Germany, the United States and Switzerland to be its significant tax jurisdictions. The majority of the Company’s earnings are derived in Germany and Switzerland. Accounting for the various federal and local taxing authorities, the statutory rates for 2023 are approximately 30.0% and 20.0% for Germany and Switzerland, respectively. The mix of earnings in those two jurisdictions resulted in an increase of approximately 4.0% from the U.S. statutory rate of 21.0% in the six months ended June 30, 2023.

12.
Earnings Per Share

The following table sets forth the computation of basic and diluted weighted average common shares outstanding and net income per common share attributable to Bruker shareholders (in millions, except per share amounts):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Net income attributable to Bruker Corporation |  | $ | 57.1 |  |  | $ | 49.5 |  |  | $ | 133.6 |  |  | $ | 111.1 |
Weighted average common shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |
Weighted average common shares outstanding - basic |  |  | 146.8 |  |  |  | 149.0 |  |  |  | 146.8 |  |  |  | 149.7 |
Effect of dilutive securities: |  |  |  |  |  |  |  |  |  |  |  |
Stock options and restricted stock units |  |  | 0.9 |  |  |  | 0.8 |  |  |  | 0.8 |  |  |  | 0.9 |
Weighted average common shares outstanding - diluted |  |  | 147.7 |  |  |  | 149.8 |  |  |  | 147.6 |  |  |  | 150.6 |
Net income per common share attributable to Bruker Corporation shareholders: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.39 |  |  | $ | 0.33 |  |  | $ | 0.91 |  |  | $ | 0.74 |
Diluted |  | $ | 0.39 |  |  | $ | 0.33 |  |  | $ | 0.91 |  |  | $ | 0.74 |

The following common share equivalents have been excluded from the computation of diluted weighted average common shares outstanding, as their effect would have been anti-dilutive (amounts in millions of shares):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Stock options |  |  | 0.2 |  |  |  | 0.1 |  |  |  | 0.2 |  |  |  | 0.1 |
Unvested restricted stock units |  |  | — |  |  |  | 0.2 |  |  |  | — |  |  |  | 0.2 |

13.
Shareholders’ Equity

Share Repurchase Program

In May 2021, the Company’s Board of Directors approved a share repurchase program (the “2021 Repurchase Program”) authorizing the purchase of up to $500.0 million of the Company’s common stock over a two-year period from time to time, in amounts, at prices, and at such times as management deems appropriate, subject to market conditions, legal requirements and other considerations. No shares were purchased during the three months ended June 30, 2023. During the six months ended June 30, 2023, the Company purchased a total of 315,318 shares at an aggregate cost of $22.2 million under the 2021 Repurchase Program. During the three months ended June 30, 2022, the Company purchased a total of 983,741 shares at an aggregate cost of $60.3 million under the 2021 Repurchase Program. During the six months ended June 30, 2022, the Company purchased a total of 2,586,796 shares at an aggregate cost of $165.9 million under the 2021 Repurchase Program. At June 30, 2023, authorization for the remaining $94.4 million on the 2021 Repurchase Program expired in May 2023.

In May 2023, the Company’s Board of Directors approved a share repurchase program (the “2023 Repurchase Program”) authorizing the purchase of up to $500.0 million of the Company’s common stock over a two-year period from time to time, in amounts, at prices, and at such times as management deems appropriate, subject to market conditions, legal requirements and other considerations. No shares were purchased during the three and six months ended June 30, 2023 under the 2023 Repurchase Program. At June 30, 2023, $500.0 million remains available for future purchase under the 2023 Repurchase Program.

On June 2, 2023, the Company filed a Form S-3ASR with the SEC (“2023 Shelf Registration”) for the issuance of common stock, preferred stock, debt securities, warrants, units, subscription rights and purchase contracts, which became effective immediately upon filing. At the time any of the securities covered by the 2023 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.

21

##### Table of Contents

In August 2022, the Inflation Reduction Act (“IRA”) was signed into law in the United States. The IRA introduced new tax provisions, including a 1.0% excise tax on stock repurchases. The Company expects additional guidance and regulations to be issued in future periods and will continue to assess its potential impact on its business as further information becomes available. The estimated excise tax on our stock repurchases was not material and was recorded in accrued expenses and additional paid in capital for the three and six months ended June 30, 2023.

Accumulated Other Comprehensive Income, net of tax

The following is a summary of comprehensive income (in millions):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Consolidated net income |  | $ | 57.8 |  |  | $ | 49.7 |  |  | $ | 135.2 |  |  | $ | 111.8 |
Foreign currency translation adjustments |  |  | 10.3 |  |  |  | (76.9 | ) |  |  | 36.1 |  |  |  | (107.4 | )
Derivatives designated as hedging instruments, net of tax |  |  | (15.9 | ) |  |  | 41.5 |  |  |  | (26.6 | ) |  |  | 62.6 |
Pension liability adjustments, net of tax |  |  | 0.7 |  |  |  | 1.6 |  |  |  | 0.8 |  |  |  | 2.1 |
Comprehensive income |  |  | 52.9 |  |  |  | 15.9 |  |  |  | 145.5 |  |  |  | 69.1 |
Less: Comprehensive income (loss) attributable to noncontrolling interests |  |  | 1.3 |  |  |  | (0.4 | ) |  |  | 2.6 |  |  |  | (0.2 | )
Less: Comprehensive loss attributable to redeemable noncontrolling interests |  |  | (0.3 | ) |  |  | (0.5 | ) |  |  | (0.3 | ) |  |  | (0.7 | )
Comprehensive income attributable to Bruker Corporation |  | $ | 51.9 |  |  | $ | 16.8 |  |  | $ | 143.2 |  |  | $ | 70.0 |

The following is a summary of the components of accumulated other comprehensive income (loss) attributable to Bruker Corporation, net of tax (in millions):

|  | Foreign Currency Translation |  |  | Derivatives Designated as Hedging Instruments |  |  | Pension Liability Adjustment |  |  | Accumulated Other Comprehensive Income |
Balance at December 31, 2022 |  | $ | (3.1 | ) |  | $ | 4.1 |  |  | $ | 13.8 |  |  | $ | 14.8 |
Other comprehensive income (loss) before reclassifications |  |  | 35.4 |  |  |  | (26.6 | ) |  |  | 0.3 |  |  |  | 9.1 |
Realized gain on amounts reclassified from other comprehensive income |  |  | — |  |  |  | — |  |  |  | 0.5 |  |  |  | 0.5 |
Net current period other comprehensive income (loss) |  |  | 35.4 |  |  |  | (26.6 | ) |  |  | 0.8 |  |  |  | 9.6 |
Balance at June 30, 2023 |  | $ | 32.3 |  |  | $ | (22.5 | ) |  | $ | 14.6 |  |  | $ | 24.4 |

Stock-Based Compensation

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (in millions):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Stock options |  | $ | 0.4 |  |  | $ | 0.4 |  |  | $ | 0.8 |  |  | $ | 0.8 |
Restricted stock units |  |  | 3.8 |  |  |  | 3.4 |  |  |  | 7.5 |  |  |  | 6.8 |
Employee Stock Purchase Plan |  |  | 0.2 |  |  |  | — |  |  |  | 0.4 |  |  |  | — |
Total stock-based compensation expense |  | $ | 4.4 |  |  | $ | 3.8 |  |  | $ | 8.7 |  |  | $ | 7.6 |

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Cost of product revenue |  | $ | 0.4 |  |  | $ | 0.3 |  |  | $ | 0.7 |  |  | $ | 0.8 |
Selling, general and administrative |  |  | 3.5 |  |  |  | 3.2 |  |  |  | 7.1 |  |  |  | 5.9 |
Research and development |  |  | 0.5 |  |  |  | 0.3 |  |  |  | 0.9 |  |  |  | 0.9 |
Total stock-based compensation expense |  | $ | 4.4 |  |  | $ | 3.8 |  |  | $ | 8.7 |  |  | $ | 7.6 |

22

##### Table of Contents

In addition to the awards above, the Company recorded stock-based compensation expense within other charges, net of $1.2 million and $5.9 million in the three months ended June 30, 2023 and 2022, respectively, and $3.4 million and $10.1 million in the six months ended June 30, 2023 and 2022, respectively, related to the Mestrelab, PreOmics, Biognosys, Zontal acquisitions and a majority owned acquisition.

At June 30, 2023, the Company expected to recognize pre-tax stock-based compensation expense of $2.4 million associated with outstanding stock option awards granted under the Company's stock plans over the weighted average remaining service period of 1.9 years. The Company also expects to recognize additional pre-tax stock-based compensation expense of $25.8 million associated with outstanding restricted stock units granted under the Company's 2016 Incentive Compensation Plan over the weighted average remaining service period of 2.1 yea rs.

14.
Other Charges, Net

The components of other charges, net were as follows (in millions):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Information technology transformation costs |  | $ | 0.6 |  |  | $ | 1.5 |  |  | $ | 1.1 |  |  | $ | 2.5 |
Restructuring charges |  |  | 0.3 |  |  |  | 2.5 |  |  |  | 0.6 |  |  |  | 2.8 |
Acquisition-related expenses, net |  |  | 2.9 |  |  |  | 8.3 |  |  |  | 5.8 |  |  |  | 13.4 |
Other |  |  | 1.6 |  |  |  | 0.2 |  |  |  | 3.2 |  |  |  | 1.3 |
Other charges, net |  | $ | 5.4 |  |  | $ | 12.5 |  |  | $ | 10.7 |  |  | $ | 20.0 |

Restructuring Initiatives

Restructuring charges include charges for various programs that were recorded in the accompanying unaudited condensed consolidated statements of income and comprehensive income. The following table sets forth the restructuring charges (in millions):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Cost of revenues |  | $ | 0.1 |  |  | $ | 1.3 |  |  | $ | 0.3 |  |  | $ | 1.4 |
Other charges, net |  |  | 0.3 |  |  |  | 2.5 |  |  |  | 0.6 |  |  |  | 2.8 |
Total |  | $ | 0.4 |  |  | $ | 3.8 |  |  | $ | 0.9 |  |  | $ | 4.2 |

The following table sets forth the changes in restructuring reserves (in millions):

|  | Total |  |  | Severance |  |  | Exit Costs |  |  | Provisions for Excess Inventory |
Balance at December 31, 2022 |  | $ | 1.8 |  |  | $ | 0.4 |  |  | $ | 0.2 |  |  | $ | 1.2 |
Restructuring charges |  |  | 0.9 |  |  |  | 0.9 |  |  |  | — |  |  |  | — |
Cash payments |  |  | (0.9 | ) |  |  | (0.7 | ) |  |  | (0.2 | ) |  |  | — |
Other, non-cash adjustments and foreign currency effect |  |  | (0.6 | ) |  |  | — |  |  |  | — |  |  |  | (0.6 | )
Balance at June 30, 2023 |  | $ | 1.2 |  |  | $ | 0.6 |  |  | $ | — |  |  | $ | 0.6 |

23

##### Table of Contents

15.
Interest and Other Income (Expense), Net

The components of interest and other income (expenses), net were as follows (in millions):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Interest income |  | $ | 1.9 |  |  | $ | 0.4 |  |  | $ | 3.3 |  |  | $ | 0.8 |
Interest expense |  |  | (3.9 | ) |  |  | (4.0 | ) |  |  | (8.1 | ) |  |  | (8.1 | )
Impairment of strategic investments |  |  | (11.4 | ) |  |  | — |  |  |  | (18.3 | ) |  |  | — |
Exchange losses on foreign currency transactions |  |  | (2.2 | ) |  |  | (0.4 | ) |  |  | (5.5 | ) |  |  | (0.5 | )
Pension components |  |  | — |  |  |  | (0.4 | ) |  |  | (0.1 | ) |  |  | (0.7 | )
Other income (expense) |  |  | 6.9 |  |  |  | 0.1 |  |  |  | 3.9 |  |  |  | 1.7 |
Interest and other income (expense), net |  | $ | (8.7 | ) |  | $ | (4.3 | ) |  | $ | (24.8 | ) |  | $ | (6.8 | )

Amounts reported in interest and other income (expense), net, include a cumulative currency translation adjustment loss of $2.7 million recognized from substantially liquidating our Russian operations during the three and six months ended June 30, 2023.

16.
Commitments and Contingencies

In accordance with Accounting Standards Codification (“ASC”) Topic 450, Contingencies, the Company accrues anticipated costs of settlement, damages or other costs to the extent specific losses are probable and reasonably estimable.

Litigation and Related Contingencies

Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. Third parties might allege that the Company or its collaborators are infringing their patent rights or that the Company is otherwise violating their intellectual property rights. The Company believes the outcome of pending proceedings, individually and in the aggregate, will not have a material impact on the Company’s consolidated financial statements.

In September 2019, Luxendo GmbH (“Luxendo”), a subsidiary of Bruker Corporation, was sued in Germany by Carl Zeiss Microscopy GmbH, a subsidiary of Carl Zeiss AG (“Zeiss”), for infringement of a registered German utility model. After the utility model was canceled by the German Patent and Trademark Office in 2021, Zeiss withdrew its infringement action at the end of 2022 and the proceedings were terminated. However, a parallel European patent application, from which the utility model was derived, is still pending in the European Patent Office (“EPO”). Luxendo filed third-party observations in the proceedings concerning the grant of the patent application and, in March 2022, the EPO communicated to the applicant that Luxendo's observations had merit, confirming the same position in October 2022. Following a hearing in April 2023, the EPO confirmed that the applicant’s main and certain auxiliary requests are invalid, but indicated that it intends to grant the patent in a combination of two original claims. If the applicant files translations of the claims and pays applicable fees before October 4, 2023, then the patent will likely be granted in the fourth quarter of 2023. Luxendo is presently unable to predict the EPO's final decision on the patent application or what steps, if any, Zeiss may take following that decision.

In addition, the Company is subject to regulation by national, state and local government agencies in the United States and other countries in which the Company operates. From time to time, the Company is the subject of governmental investigations often involving regulatory, marketing and other business practices. These governmental investigations may result in the commencement of civil and criminal proceedings, fines, penalties and administrative remedies which could have a material adverse effect on the Company's financial position, results of operations and/or liquidity.

As of June 30, 2023 and December 31, 2022, the Company has no t recorded any material accruals for potential contingencies.

24

##### Table of Contents

17. Business Segment Information

The Company has four reportable segments, BSI BioSpin, BSI CALID, BSI NANO and BEST, as discussed in Note 1 to the unaudited condensed consolidated financial statements. See Note 3 for revenue by reportable segment.

Operating income by reportable segment are presented below (in millions):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Operating income (loss): |  |  |  |  |  |  |  |  |  |  |  |
BSI BioSpin |  | $ | 23.8 |  |  | $ | 28.0 |  |  | $ | 71.2 |  |  | $ | 65.8 |
BSI CALID |  |  | 44.0 |  |  |  | 42.2 |  |  |  | 101.6 |  |  |  | 90.3 |
BSI NANO |  |  | 31.3 |  |  |  | 14.6 |  |  |  | 60.7 |  |  |  | 36.9 |
BEST |  |  | 11.1 |  |  |  | 6.6 |  |  |  | 19.1 |  |  |  | 13.2 |
Corporate, eliminations and other (a) |  |  | (24.0 | ) |  |  | (17.5 | ) |  |  | (43.7 | ) |  |  | (35.8 | )
Total operating income |  | $ | 86.2 |  |  | $ | 73.9 |  |  | $ | 208.9 |  |  | $ | 170.4 |

(a)
Represents corporate costs and eliminations not allocated to the reportable segments.

Total assets by reportable segment are as follows (in millions):

|  | June 30, 2023 |  |  | December 31, 2022 |
Assets: |  |  |  |  |  |
BSI BioSpin, BSI CALID, BSI NANO & Corporate |  | $ | 3,735.5 |  |  | $ | 3,508.4 |
BEST |  |  | 166.8 |  |  |  | 111.1 |
Eliminations and other (a) |  |  | (45.3 | ) |  |  | (7.7 | )
Total assets |  | $ | 3,857.0 |  |  | $ | 3,611.8 |

(a)
Assets not allocated to the reportable segments and eliminations of intercompany transactions.

The Company is unable, without unreasonable effort or expense, to disclose the amount of total assets held by each of its BSI BioSpin, BSI CALID and BSI NANO Segments as well as the Corporate function and further, the Company’s chief operating decision maker does not receive any asset information by operating segment.

25

##### Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our interim unaudited condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q, and in conjunction with the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022.

Statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this Quarterly Report on Form 10-Q, which express that we “believe,” “anticipate,” “plan,” “expect,” “seek,” “may,” “will,” “intend,” “estimate,” “should” and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include, but are not limited to, the impact of supply chain challenges, expectations regarding the global economy, inflation, banking industry volatility, the potential for recession, increasing geopolitical tensions, our intentions regarding our intellectual property, our compliance with government regulations, sufficiency of cash, our competition, the impact of legal or intellectual property proceedings, the impact of changes to tax and accounting rules and changes in law, our anticipated tax rate, our expectations regarding cash dividends, share repurchases, interest expense, interest rate swap agreements, expenses and capital expenditures, the impact of foreign currency exchange rates and changes in commodity prices, the impact of our restructuring initiatives, the level and impact of our M&A activity and our ability to integrate acquired companies, our expectations regarding revenue and other risk factors discussed herein and from time to time in our other filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2022 and subsequent filings. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Non-GAAP Measures

Although our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP), we believe describing revenue and expenses, excluding the effects of foreign currency, acquisitions and divestitures, as well as certain other charges, net, provides meaningful supplemental information regarding our performance. We rely internally on certain measures that are not calculated according to GAAP. These measures are organic revenue, free cash flow, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP operating income and non-GAAP operating margin. Our management believes that these financial measures provide relevant and useful information that is widely used by equity analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance. We define the term organic revenue as GAAP revenue excluding the effect of foreign currency translation changes and the effect of acquisitions and divestitures. We define the term non-GAAP gross profit as GAAP gross profit with certain non-GAAP measures excluded and non-GAAP gross profit margin as GAAP gross profit margin with certain non-GAAP measures excluded. We define the term non-GAAP operating income as GAAP operating income with certain non-GAAP measures excluded and non-GAAP operating margin as GAAP operating margin with certain non-GAAP measures excluded. These non-GAAP measures exclude costs related to restructuring actions, acquisition and related integration expenses, amortization of acquired intangible assets, costs associated with our global information technology transition initiatives, and other non-operational costs and we believe these are useful measures to evaluate our continuing business.

We define free cash flow as GAAP net cash provided by operating activities less additions to property, plant, and equipment. We believe free cash flow is a useful measure to evaluate our business as it indicates the amount of cash generated after additions to property, plant, and equipment which is available for, among other things, investments in our business, acquisitions, share repurchases, dividends and repayment of debt. We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on such non-GAAP measures and use this information for our planning and forecasting activities. These measures may also be useful to investors in evaluating the underlying operating performance of our business. The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies.

26

##### Table of Contents

OVERVIEW

We are a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Our corporate headquarters are located in Billerica, Massachusetts. We maintain major technical and manufacturing centers in Europe, Asia and North America and we have sales offices located throughout the world. Bruker is organized into four reportable segments: the Bruker Scientific Instruments (BSI) BioSpin Segment, the BSI CALID Segment, the BSI NANO Segment and the Bruker Energy & Supercon Technologies (BEST) Segment.

Revenue for the three months ended June 30, 2023 increased by $93.5 million, or 15.9%, to $681.9 million, compared to $588.4 million for the comparable period in 2022. Included in revenue was an increase of approximately $2.8 million from favorable foreign exchange rate movements, and an increase of $11.0 million from acquisitions. Excluding the favorable effects of foreign exchange rate movements and our recent acquisitions, our organic revenue, a non-GAAP measure, increased $79.7 million. Revenue increases were driven by strong demand for our differentiated high-value scientific instruments and life science solutions compared to the same period in 2022.

Revenue for the six months ended June 30, 2023 increased by $183.8 million, or 15.5%, to $1,367.2 million, compared to $1,183.4 million for the comparable period in 2022. Included in revenue was a decrease of approximately $24.3 million from unfavorable foreign exchange rate movements, partially offset by an increase of $23.7 million from acquisitions. Excluding the unfavorable effects of foreign exchange rate movements and our recent acquisitions, our organic revenue, a non-GAAP measure, increased $184.4 million. Revenue increases were driven by strong demand for our differentiated high-value scientific instruments and life science solutions compared to the same period in 2022.

Our gross profit margin decreased to 49.9% during the three months ended June 30, 2023, as compared to 50.7% in the same period in 2022, the result of favorable pricing and volume leverage offset by the net unfavorable impact of foreign exchange rate movements, costs contributed by acquisitions, inflation and unfavorable product mix compared to 2022.

Our gross profit margin increased to 51.2% during the six months ended June 30, 2023, as compared to 51.1% in the same period in 2022, the result of favorable pricing and volume leverage partially offset by net unfavorable impact of foreign exchange rate movements, inflation, and costs contributed by acquisition compared to 2022.

Our income tax provision in both the three months ended June 30, 2023 and 2022 was $19.9 million, representing effective tax rates of 25.7% and 28.6%, respectively. Our income tax provision in the six months ended June 30, 2023 and 2022 was $49.8 million and $51.8 million, respectively, representing effective tax rates of 27.1% and 31.7%, respectively. The decrease in our effective tax rate was primarily due to the impact of U.S. tax legislation that became effective in the fourth quarter of 2022 allowing a larger benefit relating to foreign tax credits, the resolution of tax controversies, and change in jurisdictional mix. The Company also recorded discrete tax impacts during the six months ended June 30, 2023.

Diluted earnings per share for the three months ended June 30, 2023 was $0.39, an increase of $0.06 compared to $0.33 per share in the same period in 2022. Diluted earnings per share for the six months ended June 30, 2023 was $0.91, an increase of $0.17 compared to $0.74 per share in the same period in 2022. The increase in diluted earnings per share in both the three and six months ended June 30, 2023 was primarily driven by higher net income and lower weighted average shares outstanding as compared to the three and six months ended June 30, 2022, due to share repurchases under our repurchase program.

The following table presents a reconciliation from net cash provided by operating activities, which is the most directly comparable GAAP operating financial measure, to free cash flow, a non-GAAP measure, as used by management (in millions):

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |
GAAP net cash provided by operating activities |  | $ | 100.5 |  |  | $ | 33.4 |
Less: purchases of property, plant and equipment |  |  | (48.5 | ) |  |  | (36.9 | )
Free cash flow |  | $ | 52.0 |  |  | $ | (3.5 | )

27

##### Table of Contents

The following table presents reconciliations from gross profit and gross profit margin, which are the most directly comparable GAAP operating performance measures, to non-GAAP gross profit and non-GAAP gross profit margin as used by management (in millions):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Gross profit |  | $ | 340.5 |  |  |  | 49.9 | % |  | $ | 298.2 |  |  |  | 50.7 | % |  | $ | 700.2 |  |  |  | 51.2 | % |  | $ | 604.5 |  |  |  | 51.1 | %
Non-GAAP adjustments: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restructuring costs |  |  | 0.1 |  |  |  | — |  |  |  | 1.3 |  |  |  | 0.2 | % |  |  | 0.3 |  |  |  | — |  |  |  | 1.4 |  |  |  | 0.1 | %
Acquisition-related costs |  |  | 0.4 |  |  |  | 0.1 | % |  |  | — |  |  |  | — |  |  |  | 0.5 |  |  |  | 0.1 | % |  |  | 0.2 |  |  |  | — |
Purchased intangible amortization |  |  | 5.6 |  |  |  | 0.8 | % |  |  | 4.5 |  |  |  | 0.8 | % |  |  | 11.0 |  |  |  | 0.8 | % |  |  | 9.0 |  |  |  | 0.8 | %
Other costs |  |  | 0.7 |  |  |  | 0.1 | % |  |  | 0.7 |  |  |  | 0.1 | % |  |  | 1.2 |  |  |  | 0.1 | % |  |  | 2.9 |  |  |  | 0.2 | %
Non-GAAP gross profit |  | $ | 347.3 |  |  |  | 50.9 | % |  | $ | 304.7 |  |  |  | 51.8 | % |  | $ | 713.2 |  |  |  | 52.2 | % |  | $ | 618.0 |  |  |  | 52.2 | %

Our non-GAAP gross profit margin decreased in the three months ended June 30, 2023 as compared to the same period in 2022, due to unfavorable product mix and impact of foreign exchange rate movements, as well as inflation. Our non-GAAP gross profit margin remained consistent in both the six months ended June 30, 2023 and 2022 with prior quarter's favorable results offsetting the performance in the current quarter.

The following table presents reconciliations from operating income and operating margin, which are the most directly comparable GAAP operating performance measures, to non-GAAP operating income and non-GAAP operating margin as used by management (in millions):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Operating income |  | $ | 86.2 |  |  |  | 12.6 | % |  | $ | 73.9 |  |  |  | 12.6 | % |  | $ | 208.9 |  |  |  | 15.3 | % |  | $ | 170.4 |  |  |  | 14.4 | %
Non-GAAP adjustments: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restructuring costs |  |  | 0.4 |  |  |  | 0.1 | % |  |  | 3.8 |  |  |  | 0.6 | % |  |  | 0.9 |  |  |  | 0.1 | % |  |  | 4.2 |  |  |  | 0.4 | %
Acquisition-related costs |  |  | 3.3 |  |  |  | 0.5 | % |  |  | 8.3 |  |  |  | 1.4 | % |  |  | 6.3 |  |  |  | 0.4 | % |  |  | 13.6 |  |  |  | 1.1 | %
Purchased intangible amortization |  |  | 11.2 |  |  |  | 1.6 | % |  |  | 9.3 |  |  |  | 1.6 | % |  |  | 21.9 |  |  |  | 1.6 | % |  |  | 18.6 |  |  |  | 1.6 | %
Other costs |  |  | 3.0 |  |  |  | 0.5 | % |  |  | 2.4 |  |  |  | 0.4 | % |  |  | 5.5 |  |  |  | 0.4 | % |  |  | 6.7 |  |  |  | 0.5 | %
Non-GAAP operating income |  | $ | 104.1 |  |  |  | 15.3 | % |  | $ | 97.7 |  |  |  | 16.6 | % |  | $ | 243.5 |  |  |  | 17.8 | % |  | $ | 213.5 |  |  |  | 18.0 | %

Our non-GAAP operating margin decreased in both the three and six months ended June 30, 2023, as due to unfavorable product mix, impact of foreign exchange rate movements and inflation experienced in the second quarter of the year compared to 2022. We also increased planned investments in sales and marketing and in our research and development capabilities, as compared to 2022.

We can experience quarter-to-quarter fluctuations in our operating results as a result of various factors, some of which are outside our control, such as:

•
general economic conditions, including inflation, uncertainties caused by the recent banking industry volatility, the threat of recession, financial liquidity, and currency volatility or devaluation, supply chain or manufacturing capabilities;
•
geopolitical tensions, including those on our customers;
•
potential energy shortages in Europe where we have significant operations and overall higher energy and transportation costs;
•
the impact of certain weather-related disruptions;
•
the timing of governmental stimulus programs and academic research budgets;
•
the time it takes between the date customer orders and deposits are received, systems are shipped and accepted by our customers and full payment is received;
•
foreign currency exchange rates;
•
changes in raw material, component and logistics costs;
•
the time it takes for us to receive critical materials to manufacture our products;
•
the time it takes to satisfy local customs requirements and other export/import requirements;

28

##### Table of Contents

•
the time it takes for customers to construct or prepare their facilities for our products;
•
the time required to obtain governmental licenses;
•
our ability to identify suitable acquisition targets and successfully integrate and manage acquired business and our overall M&A activity generally; and
•
costs related to acquisitions of technology or businesses.

Several of these factors have in the past affected and continue to affect the amount and timing of revenue recognized on sales of our products and receipt of related payments and will likely continue to do so in the future. Accordingly, our operating results in any particular quarter may not necessarily be an indication of any future quarter’s operating performance.

Maintaining business continuity and service levels to our customers

Ensuring our ability to supply our enabling technologies and solutions and maintaining high service levels for our customers is another top priority for Bruker. We are continuing capital investments in production facilities for efficiencies and expansion. We continue to encounter supply chain risks associated with the global economy and increasing geopolitical tensions, including inflation, banking industry volatility, the threat of recession, financial liquidity, currency volatility or devaluation, and the worldwide shortage of semiconductor chips, components and raw materials, such as copper.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

This discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates and judgments, including those related to: revenue recognition; stock-based compensation expense; restructuring and other related charges; income taxes, including the recoverability of deferred tax assets; allowance for doubtful accounts; inventory reductions for excess and obsolete inventories; estimated fair values of long-lived assets used to measure the recoverability of long-lived assets; intangible assets and goodwill; expected future cash flows used to measure the recoverability of intangible assets and long-lived assets; warranty costs; derivative financial instruments; and contingent liabilities. We base our estimates and judgments on our historical experience, current market and economic conditions, industry trends, and other assumptions that we believe are reasonable and form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates and historical experience.

We believe the following critical accounting policies and estimates to be both those most important to the portrayal of our financial position and results of operations and those that require the most estimation and subjective judgment:

•
Revenue recognition;
•
Income taxes;
•
Inventories;
•
Goodwill, other intangible assets and other long-lived assets; and
•
Business combinations.

For a further discussion of our critical accounting policies, please refer to our Annual Report on Form 10-K for the year ended December 31, 2022.

29

##### Table of Contents

RESULTS OF OPERATIONS

Three Months Ended June 30, 2023 compared to the Three Months Ended June 30, 2022

Consolidated Results

The following table presents our results (in millions):

|  | Three Months Ended June 30, |  |  |  |  |  |  |
|  | 2023 |  |  | 2022 |  |  | Dollar Change |  |  | Percentage Change |
Product revenue |  | $ | 559.6 |  |  | $ | 485.8 |  |  | $ | 73.8 |  |  |  | 15.2 | %
Service and other revenue |  |  | 122.3 |  |  |  | 102.6 |  |  |  | 19.7 |  |  |  | 19.2 | %
Total revenue |  |  | 681.9 |  |  |  | 588.4 |  |  |  | 93.5 |  |  |  | 15.9 | %
Cost of product revenue |  |  | 272.8 |  |  |  | 230.1 |  |  |  | 42.7 |  |  |  | 18.6 | %
Cost of service and other revenue |  |  | 68.6 |  |  |  | 60.1 |  |  |  | 8.5 |  |  |  | 14.1 | %
Total cost of revenue |  |  | 341.4 |  |  |  | 290.2 |  |  |  | 51.2 |  |  |  | 17.6 | %
Gross profit |  |  | 340.5 |  |  |  | 298.2 |  |  |  | 42.3 |  |  |  | 14.2 | %
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Selling, general and administrative |  |  | 177.9 |  |  |  | 152.2 |  |  |  | 25.7 |  |  |  | 16.9 | %
Research and development |  |  | 71.0 |  |  |  | 59.6 |  |  |  | 11.4 |  |  |  | 19.1 | %
Other charges, net |  |  | 5.4 |  |  |  | 12.5 |  |  |  | (7.1 | ) |  |  | (56.8 | )%
Total operating expenses |  |  | 254.3 |  |  |  | 224.3 |  |  |  | 30.0 |  |  |  | 13.4 | %
Operating income |  |  | 86.2 |  |  |  | 73.9 |  |  |  | 12.3 |  |  |  | 16.6 | %
Interest and other income (expense), net |  |  | (8.7 | ) |  |  | (4.3 | ) |  |  | (4.4 | ) |  |  | 102.3 | %
Income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries |  |  | 77.5 |  |  |  | 69.6 |  |  |  | 7.9 |  |  |  | 11.4 | %
Income tax provision |  |  | 19.9 |  |  |  | 19.9 |  |  |  | — |  |  |  | — |
Equity in income of unconsolidated investees, net of tax |  |  | 0.2 |  |  |  | — |  |  |  | 0.2 |  |  |  |
Consolidated net income |  |  | 57.8 |  |  |  | 49.7 |  |  |  | 8.1 |  |  |  | 16.3 | %
Net income attributable to noncontrolling interests in consolidated subsidiaries |  |  | 0.7 |  |  |  | 0.2 |  |  |  | 0.5 |  |  |  | 250.0 | %
Net income attributable to Bruker Corporation |  | $ | 57.1 |  |  | $ | 49.5 |  |  | $ | 7.6 |  |  |  | 15.4 | %

Reportable Segment Revenue

The following table presents revenue, change in revenue and revenue growth by reportable segment (in millions):

|  | Three Months Ended June 30, |  |  |  |  |  |  |
|  | 2023 |  |  | 2022 |  |  | Dollar Change |  |  | Percentage Change |
BSI BioSpin |  | $ | 162.0 |  |  | $ | 159.8 |  |  | $ | 2.2 |  |  |  | 1.4 | %
BSI CALID |  |  | 227.2 |  |  |  | 190.3 |  |  |  | 36.9 |  |  |  | 19.4 | %
BSI NANO |  |  | 225.1 |  |  |  | 182.2 |  |  |  | 42.9 |  |  |  | 23.5 | %
BEST |  |  | 72.7 |  |  |  | 59.2 |  |  |  | 13.5 |  |  |  | 22.8 | %
Eliminations (a) |  |  | (5.1 | ) |  |  | (3.1 | ) |  |  | (2.0 | ) |  |  |
Total revenue |  | $ | 681.9 |  |  | $ | 588.4 |  |  | $ | 93.5 |  |  |  | 15.9 | %

(a)
Represents product and service revenue between reportable segments.

30

##### Table of Contents

Revenue

Revenue increases were driven by strong demand for our differentiated instruments and solutions as well as pricing improvements. The BSI BioSpin Segment revenue for the three months ended June 30, 2023 was $162.0 million, an increase of 1.4% compared to the same period in 2022. The increase related primarily to the strong demand for our instruments, especially in Nuclear Magnetic Resonance (NMR) and software businesses. The BSI CALID Segment revenue for the three months ended June 30, 2023 was $227.2 million, an increase of 19.4% compared to the same period in 2022. The increase in revenues was a direct result of strong demand for our differentiated instruments. BSI NANO Segment revenue for the three months ended June 30, 2023 was $225.1 million, an increase of 23.5% compared to the same period in 2022. The increase in revenue was driven by strong demand in its academic, government, industrial and semiconductor metrology markets. The BEST revenue for the three months ended June 30, 2023 was $72.7 million, an increase of 22.8% compared to the same period in 2022, driven by strong superconductor demand from our magnetic resonance imaging original equipment manufacturer customers.

Geographically in the three months ended June 30, 2023, our North American revenue grew 5.8%, Asia Pacific revenue increased by 26.5%, and European revenue increased by 12.7% compared to the same period in 2022.

Gross Profit

While gross profit increased in the three months ended June 30, 2023, as compared to the same period in 2022, the gross profit margin decreased as a result of unfavorable product mix and foreign exchange rate movements, as well as inflation, compared to 2022.

Selling, General and Administrative

Our selling, general and administrative expenses for the three months ended June 30, 2023 increased to 26.1% of total revenue, from 25.9% of total revenue for the comparable period in 2022. The increase as a percentage of revenue was a result of inflation and increased planned investments in sales and marketing and in our research and development capabilities, as compared to 2022.

Research and Development

Our research and development expenses for the three months ended June 30, 2023 increased to 10.4% of total revenue from 10.1% of total revenue for the comparable period in 2022. The increase as a percentage of revenue is a result of our increased investment in research and development capabilities, especially in our key Project Accelerate 2.0 initiatives.

Other Charges, Net

Other charges, net for the three months ended June 30, 2023 consisted of $2.9 million of acquisition-related charges related to acquisitions completed in 2023 and 2022, $0.6 million of costs associated with our global information technology (IT) transformation activities, $1.6 million of other charges and $0.3 million of restructuring costs. Acquisition-related charges relate primarily to integration cost of newly acquired entities and the cost of post combination employment services in the period acquired. The IT transformation initiative is a multi-year project aimed at updating and integrating our global enterprise resource planning and human resource information systems.

Other charges, net for the three months ended June 30, 2022 consisted of $8.3 million of acquisition-related charges related to acquisitions completed in 2022 and 2021, $2.5 million of restructuring costs, $1.5 million of costs associated with our global information technology (IT) transformations activities, and $0.2 million of other charges.

Operating Income

The following table presents operating income and operating margins on revenue by reportable segment (in millions):

|  | Three Months Ended June 30, |
|  | 2023 |  |  | 2022 |
|  | Operating Income (Loss) |  |  | Percentage of Segment Revenue |  |  | Operating Income (Loss) |  |  | Percentage of Segment Revenue |
BSI BioSpin |  | $ | 23.8 |  |  |  | 14.7 | % |  | $ | 28.0 |  |  |  | 17.5 | %
BSI CALID |  |  | 44.0 |  |  |  | 19.4 | % |  |  | 42.2 |  |  |  | 22.2 | %
BSI NANO |  |  | 31.3 |  |  |  | 13.9 | % |  |  | 14.6 |  |  |  | 8.0 | %
BEST |  |  | 11.1 |  |  |  | 15.3 | % |  |  | 6.6 |  |  |  | 11.1 | %
Corporate, eliminations and other (a) |  |  | (24.0 | ) |  |  |  |  |  | (17.5 | ) |  |  |
Total operating income |  | $ | 86.2 |  |  |  | 12.6 | % |  | $ | 73.9 |  |  |  | 12.6 | %

(a) Represents corporate costs and eliminations not allocated to the reportable segments.

31

##### Table of Contents

The overall increase in operating income was due to higher gross profit offset by an increase in selling, general and administrative expenses and research and development.

The operating margin decreases in the BSI BioSpin and BSI CALID Segments were primarily due to unfavorable product mix, impact of foreign exchange rate movements and inflation offset by favorable pricing and volume leverage. The increase in operating margins in the BSI NANO Segment was primarily due to higher gross margin resulting from favorable product mix, pricing, volume leverage. The operating margin increase in the BEST Segment was primarily driven by volume leverage, pricing, operating efficiency, and favorable product mix.

Interest and Other Income (Expense), Net

The increase in interest and other income (expense), net in the three months ended June 30, 2023, as compared to the same period in 2022 was primarily due to impairment charges recognized of $11.4 million on certain strategic investments and higher foreign currency exchange losses of $2.2 million driven by weakening of the U.S. dollar against other currencies.

Income Tax Provision

The 2023 and 2022 effective tax rates were estimated using projected annual pre-tax income on a jurisdictional basis. Expected tax benefits, including tax credits and incentives, the impact of changes to valuation allowances and the effect of jurisdictional differences in statutory tax rates were also considered in the calculation.

The effective tax rates for the three months ended June 30, 2023 and 2022 were 25.7% and 28.6%, respectively. The decrease in our effective tax rate was primarily due to the impact of U.S. tax legislation that became effective in the fourth quarter of 2022 allowing a larger benefit relating to foreign tax credits and change in jurisdictional mix. The Company also recorded discrete tax impacts during the three months ended June 30, 2023.

Equity in Income of Unconsolidated Investees, net of tax

Equity in Income of Unconsolidated Investees, net of tax represents the Company's proportional share of the earnings or losses as reported by equity-method investees.

Net Income Attributable to Noncontrolling Interests

The net income attributable to noncontrolling interests represented the minority shareholders’ proportionate share of the net income recorded by our majority-owned subsidiaries.

32

##### Table of Contents

Consolidated Results

Six Months Ended June 30, 2023 compared to the Six Months Ended June 30, 2022

The following table presents our results (in millions):

|  | Six Months Ended June 30, |  |  |  |  |  |  |
|  | 2023 |  |  | 2022 |  |  | Dollar Change |  |  | Percentage Change |
Product revenue |  | $ | 1,126.7 |  |  | $ | 976.2 |  |  | $ | 150.5 |  |  |  | 15.4 | %
Service and other revenue |  |  | 240.5 |  |  |  | 207.2 |  |  |  | 33.3 |  |  |  | 16.1 | %
Total revenue |  |  | 1,367.2 |  |  |  | 1,183.4 |  |  |  | 183.8 |  |  |  | 15.5 | %
Cost of product revenue |  |  | 530.0 |  |  |  | 459.1 |  |  |  | 70.9 |  |  |  | 15.4 | %
Cost of service and other revenue |  |  | 137.0 |  |  |  | 119.8 |  |  |  | 17.2 |  |  |  | 14.4 | %
Total cost of revenue |  |  | 667.0 |  |  |  | 578.9 |  |  |  | 88.1 |  |  |  | 15.2 | %
Gross profit |  |  | 700.2 |  |  |  | 604.5 |  |  |  | 95.7 |  |  |  | 15.8 | %
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Selling, general and administrative |  |  | 340.6 |  |  |  | 297.9 |  |  |  | 42.7 |  |  |  | 14.3 | %
Research and development |  |  | 140.0 |  |  |  | 116.2 |  |  |  | 23.8 |  |  |  | 20.5 | %
Other charges, net |  |  | 10.7 |  |  |  | 20.0 |  |  |  | (9.3 | ) |  |  | (46.5 | )%
Total operating expenses |  |  | 491.3 |  |  |  | 434.1 |  |  |  | 57.2 |  |  |  | 13.2 | %
Operating income |  |  | 208.9 |  |  |  | 170.4 |  |  |  | 38.5 |  |  |  | 22.6 | %
Interest and other income (expense), net |  |  | (24.8 | ) |  |  | (6.8 | ) |  |  | (18.0 | ) |  |  | 264.7 | %
Income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries |  |  | 184.1 |  |  |  | 163.6 |  |  |  | 20.5 |  |  |  | 12.5 | %
Income tax provision |  |  | 49.8 |  |  |  | 51.8 |  |  |  | (2.0 | ) |  |  | (3.9 | )%
Equity in income of unconsolidated investees, net of tax |  |  | 0.9 |  |  |  | — |  |  |  | 0.9 |  |  |  |
Consolidated net income |  |  | 135.2 |  |  |  | 111.8 |  |  |  | 23.4 |  |  |  | 20.9 | %
Net income attributable to noncontrolling interests in consolidated subsidiaries |  |  | 1.6 |  |  |  | 0.7 |  |  |  | 0.9 |  |  |  | 128.6 | %
Net income attributable to Bruker Corporation |  | $ | 133.6 |  |  | $ | 111.1 |  |  | $ | 22.5 |  |  |  | 20.3 | %

Reportable Segment Revenue

The following table presents revenue, change in revenue and revenue growth by reportable segment (in millions):

|  | Six Months Ended June 30, |  |  |  |  |  |  |
|  | 2023 |  |  | 2022 |  |  | Dollar Change |  |  | Percentage Change |
BSI BioSpin |  | $ | 342.3 |  |  | $ | 317.6 |  |  | $ | 24.7 |  |  |  | 7.8 | %
BSI CALID |  |  | 463.9 |  |  |  | 393.5 |  |  |  | 70.4 |  |  |  | 17.9 | %
BSI NANO |  |  | 434.7 |  |  |  | 360.7 |  |  |  | 74.0 |  |  |  | 20.5 | %
BEST |  |  | 134.9 |  |  |  | 118.9 |  |  |  | 16.0 |  |  |  | 13.5 | %
Eliminations (a) |  |  | (8.6 | ) |  |  | (7.3 | ) |  |  | (1.3 | ) |  |  |
Total revenue |  | $ | 1,367.2 |  |  | $ | 1,183.4 |  |  | $ | 183.8 |  |  |  | 15.5 | %

(a)
Represents product and service revenue between reportable segments.

Revenue

Revenue increases were driven by strong demand for our differentiated instruments and solutions as well as pricing improvements offset by the negative impact of foreign currency translation. The BSI BioSpin Segment revenue for the six months ended June 30, 2023 was $342.3 million, an increase of 7.8% compared to the same period in 2022. The increase related primarily to the strong demand for our instruments, especially in NMR and software business. The BSI CALID Segment revenue for the six months ended June 30, 2023 was $463.9 million, an increase of 17.9% compared to the same period in 2022. The increase in revenues was a direct result of strong demand for our differentiated instruments. BSI NANO Segment revenue for the six months ended June 30, 2023 was $434.7 million, an increase of 20.5% compared to the same period in 2022. The increase in revenue was driven by strong demand in its academic, government, industrial and semiconductor metrology markets. The BEST revenue for the six months ended June 30, 2023 was $134.9 million, an increase of 13.5% compared to the same period in 2022, driven by strong superconductor demand from our magnetic resonance imaging original equipment manufacturer customers.

Geographically in the six months ended June 30, 2023, our North American revenue grew 8.4%, Asia Pacific revenue increased by 26.8%, and European revenue increased by 11.4% compared to the same period in 2022.

33

##### Table of Contents

Gross Profit

The increase in gross profit in the six months ended June 30, 2023, as compared to the same period in 2022, was a result of pricing, volume leverage, partially offset by net unfavorable impact of foreign exchange rate movements compared to 2022.

Selling, General and Administrative

Our selling, general and administrative expenses for the six months ended June 30, 2023 decreased to 24.9% of total revenue, from 25.2% of total revenue for the comparable period in 2022. The decrease as a percentage of revenue was a result of the strong revenue volumes as well as cost control measures to manage the current inflation challenges.

Research and Development

Our research and development expenses for the six months ended June 30, 2023 increased to 10.2% of total revenue from 9.8% of total revenue for the comparable period in 2022. The increase as a percentage of revenue is a result of our increased investment in research and development capabilities, especially in our key Project Accelerate 2.0 initiatives.

Other Charges, Net

Other charges, net for the six months ended June 30, 2023 consisted of $5.8 million of acquisition-related charges related to acquisitions completed in 2023 and 2022, $1.1 million of costs associated with our global information technology (IT) transformation activities, $3.2 million of other charges and $0.6 million of restructuring costs. Acquisition-related charges relate primarily to integration cost of newly acquired entities and the cost of post combination employment services in the period acquired. The IT transformation initiative is a multi-year project aimed at updating and integrating our global enterprise resource planning and human resource information systems.

Other charges, net for the six months ended June 30, 2022 consisted of $13.4 million of acquisition-related charges related to acquisitions completed in 2022 and 2021, $2.8 million of restructuring costs, $2.5 million of costs associated with our global information technology (IT) transformations activities, $0.8 million of other charges, and $0.5 million related to suspension of operations in Russia.

Operating Income

The following table presents operating income and operating margins on revenue by reportable segment (in millions):

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |
|  | Operating Income (Loss) |  |  | Percentage of Segment Revenue |  |  | Operating Income (Loss) |  |  | Percentage of Segment Revenue |
BSI BioSpin |  | $ | 71.2 |  |  |  | 20.8 | % |  | $ | 65.8 |  |  |  | 20.7 | %
BSI CALID |  |  | 101.6 |  |  |  | 21.9 | % |  |  | 90.3 |  |  |  | 22.9 | %
BSI NANO |  |  | 60.7 |  |  |  | 14.0 | % |  |  | 36.9 |  |  |  | 10.2 | %
BEST |  |  | 19.1 |  |  |  | 14.2 | % |  |  | 13.2 |  |  |  | 11.1 | %
Corporate, eliminations and other (a) |  |  | (43.7 | ) |  |  |  |  |  | (35.8 | ) |  |  |
Total operating income |  | $ | 208.9 |  |  |  | 15.3 | % |  | $ | 170.4 |  |  |  | 14.4 | %

(a) Represents corporate costs and eliminations not allocated to the reportable segments.

The overall increase in operating income was due to higher gross profit offset by an increase in selling, general and administrative expenses and research and development.

The operating income increases in the BSI BioSpin and BSI NANO Segments were primarily due to higher gross margin resulting from favorable product mix, pricing, volume leverage more than offsetting inflation. While BSI CALID's operating income increased, the operating margin decreased due to acquisition costs and unfavorable foreign exchange rate movements as well as planned marketing and research and development investments, and impact of inflation costs on margin in 2023, as compared to 2022. The operating margin increase in the BEST Segment was primarily driven by volume leverage, operating efficiency, and favorable product mix.

Interest and Other Income (Expense), Net

The increase in interest and other income (expense), net in the three months ended June 30, 2023, as compared to the same period in 2022 was primarily due to impairment charges recognized of $18.3 million on certain strategic investments and higher foreign currency exchange losses of $5.5 million driven by weakening of the U.S. dollar against other currencies.

34

##### Table of Contents

Income Tax Provision

The 2023 and 2022 effective tax rates were estimated using projected annual pre-tax income on a jurisdictional basis. Expected tax benefits, including tax credits and incentives, the impact of changes to valuation allowances and the effect of jurisdictional differences in statutory tax rates were also considered in the calculation.

The effective tax rates for the six months ended June 30, 2023 and 2022 were 27.1% and 31.7%, respectively. The decrease in our effective tax rate was primarily due to the impact of U.S. tax legislation that became effective in the fourth quarter of 2022 allowing a larger benefit relating to foreign tax credits, resolution of tax controversies, and change in jurisdictional mix. The Company also recorded discrete tax impacts during the six months ended June 30, 2023.

Equity in Income of Unconsolidated Investees, net of tax

Equity in Income of Unconsolidated Investees, net of tax represents the Company's proportional share of the earnings or losses as reported by equity-method investees.

Net Income Attributable to Noncontrolling Interests

The net income attributable to noncontrolling interests represented the minority shareholders’ proportionate share of the net income recorded by our majority-owned subsidiaries.

35

##### Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

We anticipate that our existing cash and credit facilities will be sufficient to support our operating and investing needs for at least the next twelve months. Our future cash requirements could be affected by acquisitions that we may complete, purchases of our common stock or the payment of dividends in the future. Historically, we have financed our growth and liquidity needs through cash flow generation from operations and a combination of debt financings and issuances of common stock. In the future, there are no assurances that we will continue to generate cash flow from operations or that additional financing alternatives will be available to us, if required, or if available, will be obtained on terms favorable to us.

Cash, cash equivalents and short-term investments at June 30, 2023 and December 31, 2022 totaled $574.8 million and $645.5 million, respectively, of which $421.1 million and $593.8 million, respectively, related to cash, cash equivalents and short-term investments held outside of the United States in our foreign subsidiaries, most significantly in the Netherlands, Switzerland, China and Japan.

The following table presents our cash flows from operating activities, investing activities and financing activities for the periods presented (in millions):

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |
Net cash provided by operating activities |  | $ | 100.5 |  |  | $ | 33.4 |
Net cash used in investing activities |  |  | (134.2 | ) |  |  | (44.7 | )
Net cash used in financing activities |  |  | (41.0 | ) |  |  | (297.2 | )
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  |  | 4.2 |  |  |  | (36.9 | )
Net change in cash, cash equivalents and restricted cash |  | $ | (70.5 | ) |  | $ | (345.4 | )

Cash provided by operating activities during the six months ended June 30, 2023, resulted primarily from consolidated net income adjusted for non-cash items of $225.6 million, partially offset by a change in operating assets and liabilities, net of acquisitions and divestitures of $125.1 million. The increase in net income adjusted for non-cash items was mainly due to increased revenue, gross profit, and operating income. The decrease in operating cash flows due to changes in operating assets and liabilities was primarily due to an increase in inventory, decrease in payables and accrued expenses to address supply chain challenges and to fulfill backlogs and new orders, offset by collections of receivables. Cash provided by operating activities during the six months ended June 30, 2022 resulted primarily from consolidated net income adjusted for non-cash items of $168.5 million, partially offset by a change in operating assets and liabilities, net of acquisitions and divestitures of $135.1 million. The decrease was primarily due to strategic inventory management to handle supply chain challenges, timing of tax payments partially offset by customer advances received during the period related to new orders and deferral of revenue due to supply chain challenges.

Cash used in investing activities during the six months ended June 30, 2023 resulted primarily from acquisitions of $102.7 million, purchases of property, plant and equipment of $48.5 million, and strategic investments of $9.3 million, offset by $11.8 million of proceeds from sale of strategic investment and $10.7 million of net proceeds from sales of property, plant and equipment. Cash used in investing activities during the six months ended June 30, 2022 resulted primarily from acquisitions of $85.4 million, purchases of property, plant and equipment of $36.9 million, and strategic investments of $38.1 million, offset by maturity of short-term investments of $100.0 million and $13.8 million of net proceeds from sale of property, plant and equipment.

Net cash used in financing activities during the six months ended June 30, 2023 was primarily from cash paid for purchases of common stock under our repurchase program of $22.4 million and $14.7 million for the payment of dividends. Net cash used in financing activities during the six months ended June 30, 2022 was primarily from cash paid for purchases of common stock under our repurchase program of $165.9 million, repayment of our 2012 Note Purchase Agreement of $105.0 million and $15.0 million for the payment of dividends.

Share Repurchase Program

In May 2021, our Board of Directors approved a share repurchase program (the “2021 Repurchase Program”) authorizing the purchase of up to $500.0 million of our common stock over a two-year period from time to time, in amounts, at prices, and at such times as we deem appropriate, subject to market conditions, legal requirements and other considerations. No shares were purchased during the three months ended June 30, 2023. During the six months ended June 30, 2023, we purchased a total of 315,318 shares at an aggregate cost of $22.2 million under the 2021 Repurchase Program. During the three months ended June 30, 2022, we purchased a total of 983,741 shares at an aggregate cost of $60.3 million under the 2021 Repurchase Program. During the six months ended June 30, 2022, we purchased a total of 2,586,796 shares at an aggregate cost of $165.9 million under the 2021 Repurchase Program. At June 30, 2023, authorization for the remaining $94.4 million on the 2021 Repurchase Program expired in May 2023.

36

##### Table of Contents

In May 2023, our Board of Directors approved a share repurchase program (the “2023 Repurchase Program”) authorizing the purchase of up to $500.0 million of our common stock over a two-year period from time to time, in amounts, at prices, and at such times as we deem appropriate, subject to market conditions, legal requirements and other consideration. No shares were purchased during the three and six months ended June 30, 2023 under the 2023 Repurchase Program. At June 30, 2023, $500.0 million remains available for future purchase under the 2023 Repurchase Program.

On June 2, 2023, we filed a Form S-3ASR with the SEC (“2023 Shelf Registration”) for the issuance of common stock, preferred stock, debt securities, warrants, units, subscription rights and purchase contracts, which became effective immediately upon filing. At the time any of the securities covered by the 2023 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.

In August 2022, the Inflation Reduction Act (“IRA”) was signed into law in the United States. The IRA introduced new tax provisions, including a 1.0% excise tax on stock repurchases. We expect additional guidance and regulations to be issued in future periods and will continue to assess its potential impact on our business as further information becomes available. The estimated excise tax on stock repurchases was not material and was recorded in accrued expenses and additional paid in capital for the three and six months ended June 30, 2023.

Credit Facilities

On December 7, 2021, we entered into a note purchase agreement to issue and sell CHF 300 million aggregate principal amount of 0.88% series A senior notes and EUR 150 million aggregate principal amount of 1.03% series B senior notes due December 8, 2031. We designated our CHF 300 million series A senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. We designated our EUR 150 million series B senior notes as a hedge in our net investment in our EUR denominated net assets. Proceeds of the notes will be used for general corporate purposes.

On December 11, 2019, we entered into (1) a new revolving credit agreement to establish a new revolving credit facility in the aggregate principal amount of $600 million; (2) a term loan agreement to establish a new term loan facility in the aggregate principal amount of $300 million; and (3) a note purchase agreement to issue and sell CHF 297 million aggregate principal amount of 1.01% senior notes due December 11, 2029. Floating interest rates under the term loan were simultaneously fixed through cross-currency and interest rate swap agreements into Euro ($150 million) and Swiss Franc ($150 million) rates carrying average effective interest rates of 0.94% and hedge our net investment in our Euro and Swiss Franc denominated net assets.

In addition, we designated our CHF 297 million senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. Proceeds from this financing were used to repay the outstanding borrowings under our prior 2015 revolving credit facility and we intend to use the remaining proceeds for general corporate purposes and to support corporate strategic objectives. During December 2019, we entered into U.S. Dollar to Euro cross-currency swaps on our existing 2012 private placement notes of $105 million 4.31% Series 2012A Senior Notes, Tranche C, repaid in January 2022, and the existing $100 million of 4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024, resulting in an average effective interest rate of 2.25% on these instruments. The cross-currency swaps hedge our net investment in our Euro denominated net assets.

As of June 30, 2023, we have several cross-currency and interest rate swap agreements with a notional value of $142.9 million of U.S. dollar to Swiss Franc and a notional value of $242.9 million of U.S. dollar to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of our Euro and Swiss Franc denominated net asset investments. As a result of entering into these agreements, the Company lowered net interest expense by $4.6 million and $1.6 million during the three months ended June 30, 2023 and 2022, respectively, and $8.9 million and $2.7 million during the six months ended June 30, 2023 and 2022, respectively. We anticipate these swap agreements will lower net interest expense in future years.

On September 30, 2022, we entered into the Second Amendment to the 2019 Term Loan Agreement and the Second Amendment to the 2019 Credit Agreement (collectively, the “Amendments”), to modify certain aspects of the 2019 Term Loan Agreement and 2019 Credit Agreement, respectively. The Amendments modify the reference rate thereunder from London Interbank Offered Rate (“LIBOR”) to Secured Overnight Financing Rate (“SOFR”). There were no other changes to the 2019 Term Loan Agreement or 2019 Credit Agreement as a result of the Amendments. We did not record any gains or losses on the conversion of the reference rate for borrowings under the Term Loan Agreement from LIBOR to SOFR.

37

##### Table of Contents

On June 16, 2022, we entered into the First Amendment to the 2019 Credit Agreement to modify certain contract definitions within the agreement. Primarily, the current LIBOR rates were changed to new alternative base rates for the respective currencies. As part of the change any related items, such as fall-back rates and day conventions were also changed. No other material terms were modified with this agreement. During 2022, we adopted the practical expedient for Reference Rate Reform related to its debt arrangements and as such, this amendment is treated as a continuation of the existing debt agreements and no gain or loss on the modification was recorded.

We had the following debt outstanding (in millions):

|  | June 30, 2023 |  |  | December 31, 2022 |
EUR notes (in U.S. Dollars) under the 2021 Note Purchase Agreement |  | $ | 163.8 |  |  | $ | 160.6 |
CHF notes (in U.S. Dollars) under the 2021 Note Purchase Agreement |  |  | 335.4 |  |  |  | 325.1 |
CHF notes (in U.S. Dollars) under the 2019 Note Purchase Agreement |  |  | 332.0 |  |  |  | 321.9 |
U.S. Dollar notes under the 2019 Term Loan Agreement |  |  | 285.8 |  |  |  | 293.3 |
U.S. Dollar notes under the 2012 Note Purchase Agreement |  |  | 100.0 |  |  |  | 100.0 |
Unamortized debt issuance costs |  |  | (1.5 | ) |  |  | (1.7 | )
Other loans |  |  | 7.8 |  |  |  | 5.9 |
Total notes and loans outstanding |  |  | 1,223.3 |  |  |  | 1,205.1 |
Finance lease obligations |  |  | 20.1 |  |  |  | 14.1 |
Total debt |  |  | 1,243.4 |  |  |  | 1,219.2 |
Current portion of long-term debt and finance lease obligations |  |  | (120.9 | ) |  |  | (18.7 | )
Total long-term debt, less current portion |  | $ | 1,122.5 |  |  | $ | 1,200.5 |

As of June 30, 2023, we had no off-balance sheet arrangements.

The following is a summary of the maximum commitments and the net amounts available to us under the 2019 Credit Agreement and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at June 30, 2023 (in millions):

|  | Weighted Average Interest Rate |  | Total Amount Committed by Lenders |  |  | Outstanding Borrowings |  |  | Outstanding Letters of Credit |  |  | Total Amount Available |
2019 Credit Agreement |  | 0.15% |  | $ | 600.0 |  |  | $ | — |  |  | $ | 0.4 |  |  | $ | 599.6 |
Bank guarantees and working capital line |  | varies |  |  | 140.4 |  |  |  | — |  |  |  | 140.4 |  |  |  | — |
Total revolving lines of credit |  |  |  | $ | 740.4 |  |  | $ | — |  |  | $ | 140.8 |  |  | $ | 599.6 |

As of June 30, 2023, we were compliant with the financial covenants of these debt agreements.

RECENT ACCOUNTING PRONOUNCEMENTS

Information regarding recent accounting standard changes and developments is incorporated by reference from Part I, Item 1, Unaudited Condensed Consolidated Financial Statements, of this document and should be considered an integral part of this Item 2. See Note 2 in the Notes to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for recently adopted and issued accounting standards.

38

##### Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are potentially exposed to market risks associated with changes in foreign currency translation rates, interest rates and commodity prices. We selectively use financial instruments to reduce these risks. All transactions related to risk management techniques are authorized and executed pursuant to our policies and procedures. Analytical techniques used to manage and monitor foreign currency translation and interest rate risk include market valuations and sensitivity analysis.

Foreign Currency Risk

We generate a substantial portion of our revenues in international markets, principally Germany and other countries in the European Union, Switzerland and Japan, which exposes our operations to the risk of exchange rate fluctuations. The impact of currency exchange rate movements can be positive or negative in any period. Our costs related to sales in foreign currencies are largely denominated in the same respective currencies, reducing our transaction risk exposure. However, for foreign currency denominated sales in certain regions, such as Japan, where we do not incur significant costs denominated in Japanese Yen, we are more exposed to the impact of foreign currency fluctuations.

For sales not denominated in U.S. dollars, if there is an increase in the rate at which a foreign currency is exchanged for U.S. dollars, it will require more of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In such cases, if we price our products in the foreign currency, we will receive less in U.S. dollars than we would have received before the rate increase went into effect. If we price our products in U.S. dollars and competitors price products in local currency, an increase in the relative strength of the U.S. dollar could result in our prices not being competitive in a market where business is transacted in the local currency. For example, if the U.S. dollar strengthened against the Japanese Yen, our Japanese-based competitors would have a greater pricing advantage over us.

Changes in foreign currency translation rates increased our revenue by 0.5% and decreased our revenue by 7.3% for the three months ended June 30, 2023 and 2022, respectively. Changes in foreign currency translation rates decreased our revenue by 2.1% and by 5.8% for the six months ended June 30, 2023 and 2022, respectively.

Assets and liabilities of our foreign subsidiaries, where the functional currency is the local currency, are translated into U.S. dollars using period-end exchange rates. Revenues and expenses of foreign subsidiaries are translated at the average exchange rates in effect during the year. Adjustments resulting from financial statement translations are included as a separate component of shareholders’ equity. For the three months ended June 30, 2023 and 2022, we recorded net gains (losses) from currency translation adjustments of $10.3 million and $(76.9) million, respectively. For the six months ended June 30, 2023 and 2022, we recorded net gains (losses) from currency translation adjustments of $36.1 million and $(107.4) million, respectively. Gains and losses resulting from foreign currency transactions are reported in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income. Amounts reported in interest and other income (expense), net, include a cumulative currency translation adjustment loss of $2.7 million recognized from substantially liquidating our Russian operations during the three and six months ended June 30, 2023.

We periodically enter into forward currency contracts in order to minimize the volatility that fluctuations in currency translation have on our monetary transactions. Under these arrangements, we typically agree to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. dollars or other currencies on specified dates with maturities of less than twelve months, with some agreements extending to longer periods. These transactions do not qualify for hedge accounting and, accordingly, the instrument is recorded at fair value with the corresponding gains and losses recorded in the unaudited condensed consolidated statements of income and comprehensive income.

As of June 30, 2023, we have several cross-currency and interest rate swap agreements with a notional value of $142.9 million of U.S. dollar to Swiss Franc and a notional value of $242.9 million of U.S. dollar to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of our Euro and Swiss Franc denominated net asset investments. Under the GAAP hedge accounting guidance, changes in fair value of the derivative that relates to changes in the foreign currency spot rate are recorded in the currency translation adjustment in comprehensive income (loss) and remain in accumulated comprehensive income (loss) in shareholders’ equity until the sale or substantial liquidation of the foreign operation. For the three months ended June 30, 2023 and 2022, we recorded net gains (losses) from the changes in fair value of the derivatives of $(4.1) million and $18.0 million, respectively. For the six months ended June 30, 2023 and 2022, we recorded net gains (losses) from the changes in fair value of the derivatives of $(8.7) million and $30.1 million, respectively.

39

##### Table of Contents

On December 7, 2021, we entered into a note purchase agreement, referred to as the 2021 Note Purchase Agreement, with a group of institutional accredited investors. Pursuant to the 2021 Note Purchase Agreement, we issued and sold CHF 300 million aggregate principal amount of 0.88% series A senior notes and EUR 150 million aggregate principal amount of 1.03% series B senior notes due December 8, 2031. We designated our CHF 300 million series A senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. We designated our EUR 150 million series B senior notes as a hedge in our net investment in our Euro denominated net assets. Accordingly, the change in fair value of the 2021 Note Purchase Agreement is recorded in other comprehensive income within derivatives designated as hedging instruments, net of tax.

On December 11, 2019, we entered into a note purchase agreement, referred to as the 2019 Note Purchase Agreement, with a group of institutional accredited investors. Pursuant to the 2019 Note Purchase Agreement, we issued and sold CHF 297 million aggregate principal amount of 1.01% senior notes due December 11, 2029. We designated our CHF 297 million senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. Accordingly, the change in fair value of the 2019 Note Purchase Agreement is recorded in other comprehensive income within derivatives designated as hedging instruments, net of tax.

For the three months ended June 30, 2023 and 2022, we recorded net gains (losses) from the changes in fair value, net of tax, of the 2021 Note Purchase Agreement and the 2019 Note Purchase Agreement of $(11.8) million and $23.5 million, respectively. For the six months ended June 30, 2023 and 2022, we recorded net gains (losses) from the changes in fair value, net of tax, of the 2021 Note Purchase Agreement and the 2019 Note Purchase Agreement of $(17.9) million and $32.5 million, respectively.

From time to time, we have entered into forward exchange contracts designed to minimize the volatility that fluctuations in foreign currency have on our cash flows related to purchases and sales denominated in foreign currencies. Under these arrangements, we agree to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. dollars or other currencies on specified dates typically with maturities of less than twelve months with some agreements extending to longer periods. These transactions are recorded at fair value with the corresponding gains and losses recorded in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income. At June 30, 2023 and December 31, 2022, we had foreign exchange contracts with notional amounts aggregating $267.0 million and $187.2 million, respectively. We will continue to evaluate our currency risks and, in the future, may utilize foreign currency contracts more frequently.

Interest Rate Risk

We regularly invest excess cash in short-term investments that are subject to changes in interest rates. We believe that the market risk arising from holding these financial instruments is minimal because of our policy of investing in short-term financial instruments issued by highly rated financial institutions.

Our exposure related to adverse movements in interest rates is derived primarily from outstanding floating rate debt instruments that are indexed to short-term market rates. We currently have a higher level of fixed rate debt than variable rate debt, which limits the exposure to adverse movements in interest rates.

Commodity Price Risk

We are exposed to certain commodity risks associated with prices for various raw materials. The prices of copper and certain other raw materials, particularly niobium-tin, used to manufacture superconductors, have increased significantly over the last decade. Copper and niobium-tin are the main components of low temperature superconductors and continued commodity price increases for copper and niobium, as well as other raw materials, may negatively affect our profitability. Periodically, we enter into commodity forward purchase contracts to minimize the volatility that fluctuations in the price of copper have on our sales of these products. At June 30, 2023 and December 31, 2022, we had fixed price commodity contracts with notional amounts aggregating $10.5 million and $8.9 million, respectively. The fair value of the fixed price commodity contracts at June 30, 2023 and December 31, 2022 was $(0.1) million and $0.6 million, respectively. As commodity contracts settle, gains (losses) as a result of changes in fair values are adjusted to the contracts with the customers through revenues. We will continue to evaluate our commodity risks and may utilize commodity forward purchase contracts more frequently in the future.

Inflation Risk

We are subject to inflationary cost pressures across global supply chain networks. Certain components, parts, or materials are experiencing significant cost pressures that have impacted or may impact our cost of operations in future periods. Further, inflation has increased our general and administrative expenses and may vary between countries in which we operate. We continue to evaluate these cost increases in relation to our new orders and may continue to see a negative impact on our financial results for a period of time.

40

##### Table of Contents

Credit Risk

Economic conditions remain volatile and continue to be affected by inflation, high interest rates, supply chain disruptions and recent bank failures. We have cash and investments with certain banking institutions and money market funds in the United States and Europe where we have operations that have been the subject of concern regarding their financial conditions. Cash and investments held in these accounts exceed the Federal Deposit Insurance Corporation insurance limits. In the event of failure of any of the banking institutions where we maintain our cash and investments, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. We have a risk assessment process to evaluate the Company’s credit counter parties and we continue to closely monitor the developments in the financial markets and take steps to minimize potential impact to our business.

ITEM 4. CONTROLS AND PROCEDURES

We have established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)) that are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer and principal accounting officer) by others within our organization. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2023. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2023.

Management concluded that the unaudited condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q fairly state, in all material respects, our financial condition, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America.

Changes in Internal Controls over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

41

##### Table of Contents

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are involved in lawsuits, claims, and proceedings, including, but not limited to, patent, customer, labor and employment and commercial matters, which arise in the ordinary course of business. There are no such matters pending that we currently believe are reasonably likely to have a material impact on our business or to our condensed consolidated financial statements. No assurances can be given with respect to the extent or outcome of any investigation, litigation or dispute.

In September 2019, Luxendo GmbH (“Luxendo”), a subsidiary of Bruker Corporation, was sued in Germany by Carl Zeiss Microscopy GmbH, a subsidiary of Carl Zeiss AG (“Zeiss”), for infringement of a registered German utility model. After the utility model was canceled by the German Patent and Trademark Office in 2021, Zeiss withdrew its infringement action at the end of 2022 and the proceedings were terminated. However, a parallel European patent application, from which the utility model was derived, is still pending in the European Patent Office (“EPO”). Luxendo filed third-party observations in the proceedings concerning the grant of the patent application and, in March 2022, the EPO communicated to the applicant that Luxendo's observations had merit, confirming the same position in October 2022. Following a hearing in April 2023, the EPO confirmed that the applicant’s main and certain auxiliary requests are invalid, but indicated that it intends to grant the patent in a combination of two original claims. If the applicant files translations of the claims and pays applicable fees before October 4, 2023, then the patent will then likely be granted in the fourth quarter of 2023. Luxendo is presently unable to predict the EPO's final decision on the patent application or what steps, if any, Zeiss may take following that decision.

In addition, we are subject to regulation by national, state and local government agencies in the United States and other countries in which we operate. From time to time, we are the subject of governmental investigations often involving regulatory, marketing and other business practices. These governmental investigations may result in the commencement of civil and criminal proceedings, fines, penalties and administrative remedies which could have a material adverse effect on our financial position, results of operations and/or liquidity.

ITEM IA. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, which could materially affect our business, financial condition or future results. The risks described in this report and in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Pursuant to a share repurchase program approved by the Board of Directors and announced on May 12, 2023 (the “2023 Repurchase Program”), the Company is permitted to purchase up to $500 million of shares of its common stock over a two-year period. The Company did not make any purchases of its common stock during the quarter ended June 30, 2023.

ITEM 5. OTHER INFORMATION

Rule 10b-5 Trading Plans

During the quarter ended June 30, 2023, none of the Company's directors or officers informed the Company of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as those terms are defined in Regulation S-K, Item 408.

42

##### Table of Contents

ITEM 6. EXHIBITS

Exhibit No. | Description
31.1* | Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2* | Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1* | Certification by Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS* | Inline XBRL Instance Document
101.SCH* | Inline XBRL Taxonomy Extension Schema Document
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104* | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 has been formatted in Inline XBRL (included in Exhibit 101)

* Filed or furnished herewith.

43

##### Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 9, 2023 |  | BRUKER CORPORATION
|  | By: | /s/ FRANK H. LAUKIEN, PH.D.
|  |  | Frank H. Laukien, Ph.D.
|  |  | President, Chief Executive Officer and Chairman
|  |  | (Principal Executive Officer)
Date: August 9, 2023 |  | By: | /s/ GERALD N. HERMAN
|  |  | Gerald N. Herman
|  |  | Executive Vice President and Chief Financial Officer
|  |  | (Principal Financial Officer and Principal Accounting Officer)

44